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ABSTRACT OF DISSERTATION 
RESIDUAL NEXT-DAY EFFECTS OF ALPRAZOLAM ON PSYCHOMOTOR 
PERFORMANCE AND SIMULATED DRIVING IN HEALTHY NORMAL VOLUNTEERS 
The prevalence of drugged driving has increased in the United States, and some 
prescription medications (e.g., zolpidem) cause impairment after the predicted duration of 
therapeutic action has elapsed.  The aim of this study is to determine if bedtime administration of 
alprazolam similarly impacts driving performance the following day.   
Volunteers were 14 healthy adults (6 males) who completed a double-blind, double-
dummy within-subjects design study examining the effects of alprazolam (0.5, 1, & 2mg), zolpidem 
(10mg), and placebo administered at bedtime on driving performance the following day.  The 
positive control condition was alprazolam (1mg) administered on the test morning.  Driving 
simulator measures, cognitive and psychomotor tasks, and questionnaires querying drug effects 
were collected the afternoon before drug administration and for 5.5 hours the next day and analyzed 
using symmetry and mixed-model approaches.  The positive control was robustly impairing. 
Driving impairment equivalent to that seen with alcohol at the legal limit was observed up to 12.5hr 
after bedtime alprazolam 2mg and for 8.5hr after bedtime zolpidem 10mg.  Volunteers were not 
fully aware of their own level of impairment.  These results suggest that alprazolam used before 
bed may pose an as yet unrecognized public safety risk in the form of next-day drugged-driving.   
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CHAPTER I.  INTRODUCTION 
 2 
 PART I.  Driving Under the Influence of Alcohol and/or Drugs (DUIAD) 
Traffic accidents are a leading cause of unintentional death in the United States, second only to 
unintentional poisonings (Murphy et al. 2017).  Approximately 40,000 persons died as a result of 
a motor vehicle accident in 2017 (NSC 2018).  Unfortunately, traffic fatality rates have been 
increasing since 2014, even after accounting for population growth and increased vehicle miles 
driven annually (see Table 1.1).  Many factors contribute to traffic accidents and resultant deaths 
(e.g., speeding, bad weather, use of a seatbelt, etc.), but one consistently significant predictor of 
traffic fatality risk is driver impairment; more specifically, impairment due to use of alcohol 
and/or drugs.  While the number of deaths associated with drunk driving has decreased over the 
past 10 years (Berning et al. 2015), the frequency of drugged driving (i.e., driving under the 
influence of a potentially impairing medication or drug) has increased.  These trends are 
consistent across self-report surveys (i.e., National Survey on Drug Use and Health), voluntary 
roadside drug tests (i.e., National Roadside Survey), and drug test results from drivers involved in 
fatal accidents recorded in the National Highway Traffic Safety Administration’s (NHTSA) 
federal registry (Fatality Analysis Reporting System).  The increase in drugged driving frequency 
and associated deaths represents a nascent target for public health and safety efforts to prevent 
further morbidity and mortality.  Consequently, both the White House Office of Drug Control 
Policy and the National Institute on Drug Abuse have identified drugged driving as a research 
priority (NIDA 2014, ONDCP 2014).   
 
Prevalence  
According to the National Survey on Drug Use and Health (NSDUH), an annual nationwide 
survey of persons aged 12 and older, in 2014, 27.7 million people aged 16 or older (11.1 percent) 
drove under the influence of alcohol in the past year.  The percentage of people aged 16 or older 
who drove under the influence of alcohol in 2014 was lower than the percentages in 2002 through 
2012 (ranging from 11.8 to 15.3 percent).  Approximately 10.5 million people over the age of 16 
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drove under the influence of illicit drugs in the past year in 2005 (SAMHSA 2006) and 11.8 
million people drove under the influence of illicit drugs in 2016 (SAMHSA 2017).  The 2016 
number includes 10.9 million persons who report use of marijuana (even in states where it had 
been legalized for recreational use [i.e., Colorado, Washington, Oregon, Alaska] before 2016; the 
year of the most recent survey wave).  The survey did not query behavior related to driving under 
the influence of potentially impairing prescription drugs; nevertheless, the results are 
demonstrative of an increased pervasiveness of drug-induced impaired driving.  
 
The National Roadside Survey, conducted in 1973, 1986, 1996, 2007, and most recently in 2014, 
collects information from ~11,000 drivers who voluntarily stop at 300 research sites around the 
U.S.  Road signs alert drivers to a voluntary paid survey ahead.  The drivers answer questions 
about their driving habits, health, and can choose to provide biological samples (e.g., breath, 
saliva, urine) for alcohol and/or drug testing.  Results are completely anonymous.  Testing of 
urine and/or saliva for illegal drugs, prescription medicines, and over-the-counter drugs was 
conducted in the most recent two survey waves (2007 and 2014) only.  Since the first NRS was 
conducted in 1973, the proportion of drivers with measurable alcohol levels has declined by 
nearly 80%, and in the most recent survey wave, there were 8.3% of drivers with some 
measurable alcohol level (Kahn 2015).  In contrast, approximately 20% of drivers tested positive 
for at least one potentially impairing drug (illicit or prescription) in 2014 (Berning et al. 2015), up 
from 16.3% in 2007 (Lacey et al. 2009).  Because the survey is voluntary, these numbers may be 
an underrepresentation of the percentage of drivers who would test positive for alcohol and/or 
drugs in a truly random sample, as impaired drivers (or those who believe they would test 
positive) may choose to not participate out of fear of legal repercussions.  These survey results 
(indicative of falling drunk driving and rising drugged driving frequency) are substantiated by a 
rising prevalence of positive drug test results obtained from drivers involved in fatal accidents. 
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DUIAD as a Causal Factor in Traffic Fatalities 
Fatality Analysis Reporting System Statistics:  Since 1975, the National Highway Traffic Safety 
Administration (NHTSA) has maintained the Fatality Analysis Reporting System (FARS), a 
federal registry with data on traffic crashes resulting in a death (either of the vehicle occupant or a 
non-occupant such as pedestrian) within 30 days of the crash.  The database allows for imputation 
of over 100 coded variables describing the driver (e.g., age, race, previous DUIs, license state, 
drug test results), vehicle (e.g., make, model, year, previous damage, impact points), pre-crash 
conditions (e.g., weather, time of day, road type, location), occupant (e.g., seating position, 
seatbelt use, injury severity), and non-occupants (e.g., age, sex, alcohol and drug involvement).  
Once collated, NHTSA provides these data to the public.   
 
Data in Tables 1.2 through 1.6 were derived from the FARS interface (NHTSA), and detailed 
query terms used for each outcome are documented in Appendix 1.  Tables 1.2 and 1.4 describe 
alcohol and drug test statistics for all fatally injured drivers who tested positive for alcohol or 
drugs at autopsy.  Statistics from this group are those typically described in briefings and 
government documents regarding drunk and drugged driving.  Also relevant are all the drivers 
involved in a fatal accident—whether the death was the driver themselves or another person 
(pedestrian, passenger, etc.).  These numbers reflect all traffic deaths possibly attributable to 
impaired driving, and the alcohol and drug testing statistics for this group are displayed in Tables 
1.3 and 1.5.  The trends are similar for both groups (drivers involved in fatal accidents and fatally 
injured drivers) across the 10 most recent years for which data are available (2007 – 2016).  The 
total number of driver deaths was lowest in 2011 and has increased since that time—8,100 more 
driver deaths occurred in 2016 than 2011.   
 
The number of drivers involved in fatal accidents who were tested for alcohol remained steady at 
~49% from 2007 to 2015 but dropped precipitously to ~40% in 2016.  Fatally injured drivers 
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were tested for alcohol ~75% of the time up until 2016 when the percentage dropped to ~61.  The 
absolute number of drivers (either involved or fatally injured) testing positive for alcohol are 
generally decreasing, and this is not likely a function of the decrease in the number of drivers 
tested for alcohol as the percentage testing positive is also generally decreasing.  The percentage 
of drivers involved in fatal accidents and those fatally injured who are tested for drugs remained 
steady from 2007 to 2015, but (as with alcohol testing) dropped precipitously in 2016, so that 
only about a third of drivers involved in a fatal accident are tested for drugs.  Unlike the alcohol 
results, there has been a general increase in the number of drivers testing positive for drugs. In 
fact, in 2011, a higher percentage of drivers tested positive for drugs than alcohol and this has 
been the case for every year since.  Fatally injured drivers are more likely to be tested for alcohol 
and drugs than drivers involved in a fatal accident; though the percentage testing positive for 
drugs and alcohol in both groups are similar.  
 
Challenges in data collection and interpretation:  Estimating the number of deaths attributed to 
drugged driving is methodologically challenging for several reasons.  First, not all drivers 
involved in fatal accidents are tested for drugs (and those who are drug tested do not always have 
results available in the federal registry).  The percentage of fatally injured drivers who are tested 
for drugs has remained relatively stable for the past decade, except for a marked drop in 2016 (see 
Table 1.4).  Second, states use different methods of drug testing both in surviving drivers and 
during the autopsy of fatally injured drivers; there is not a consistent policy governing when or 
how drug testing must proceed.  As such, there is considerable variation in who is tested, which 
drugs are tested for, the type of test/equipment that is used, the sensitivity of the tests that are 
used, and which biological specimen (blood, urine, or saliva) is tested.  Furthermore, if alcohol is 
present (as is the case for ~ 23 – 30% of fatally injured drivers per year), the driver is less likely 
to be also tested for drugs because state laws often fail to distinguish between alcohol and drug 
impairment.  An alcohol test is easy and cheap compared to a drug test; particularly if the drug 
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assay used is sophisticated enough to determine drug concentrations (e.g., GCMS).  Finally, a 
causal relationship between any detected drugs and the fatal crash cannot be definitely established 
for several reasons.   
 
The presence of a drug in a person’s blood is not a guarantee of impairment.  Some drugs, like 
marijuana and diazepam, can be detected in the blood for weeks after their use (long after the 
impairing effects would have dissipated).  This is particularly relevant because in 2015, over one-
third of the fatally injured drivers who were tested for drugs during autopsy tested positive for 
marijuana.  For impairing drugs with shorter windows of detection or with half-lives that more 
closely mirror duration of action, there is perhaps a greater possibility of impairment at the time 
of a positive test; however, factors such as drug tolerance and individual differences in drug 
response still make assumptions of impairment based on positive drug test results tenuous.  There 
are multiple types of tolerance which can develop in response to repeated exposure to alcohol or 
drugs, and all can affect the level of impairment caused by ingestion of the substance.  As an 
example, functional tolerance manifests in chronic heavy drinkers when they show few overt 
signs of intoxication (e.g., slurred speech, increased body sway, etc.) even at blood alcohol 
concentrations that would be incapacitating or even fatal in those who drink less frequently 
(Lipscomb and Nathan 1980, Bennett et al. 1993).  Environment-dependent tolerance occurs 
when a substance is administered in the same environment or context (e.g., at a bar).  Rats 
repeatedly administered alcohol in one room and placebo in a different room exhibited tolerance 
to the sedative and body temperature-lowering effects of alcohol only in the alcohol-specific 
environment (Mansfield and Cunningham 1980).  A similar procedure used in humans revealed 
similar results: alcohol-induced heart rate elevations were blunted in the alcohol-paired room 
compared to a novel room (Dafters and Anderson 1982).  Similar tolerance was observed for 
social drinkers performing simple psychomotor tasks in a bar-like environment compared to an 
office.  Performance was better in the bar than the office (McCusker and Brown 1990).  Learned 
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tolerance refers to when a person displays improved task performance while intoxicated after 
practicing that task repeatedly while under the influence of that impairing substance.  
Importantly, the learning is state dependent, so practicing the task while sober does not help as 
much as practicing while under the influence (Sdao-Jarvie and Vogel-Sprott 1992).  
Environment-dependent and learned tolerance have important implications for driving while 
under the influence of drugs and/or alcohol.  While practicing a task (e.g., driving) under the 
influence of an impairing substance can lead to task improvement, it is crucially important to note 
that the tolerance developed is context specific and does not apply to novel situations such as a 
new route, a deer running in front of the car, or bad weather (Siegel and Sdao-Jarvie 1986). 
 
Despite the limitations inherent to survey and toxicology data, what can be said with some degree 
of certainty is that: 1) the percentage of persons self-disclosing drugged driving and/or drivers 
testing positive for drugs and 2) the percentage of drivers involved in and those killed in traffic 
accidents who test positive for at least one drug (illicit or prescription) are both increasing.   
 
 
The Role of Prescription Drug Use in DUIAD and Traffic Fatalities 
Drugged driving can occur after use of illicit drugs such as methamphetamine, cocaine, and 
heroin but also after use of prescription drugs such as opioids or benzodiazepines.  Almost 20% 
of drivers queried about prescription drug use as part of the NRS (Berning et al. 2015) disclosed 
use within the past 2 days, with the most common drug classes reported as: sedatives including 
sleep aids and benzodiazepines (8.0%), followed by antidepressants (7.7%), narcotics including 
opiates (7.5%), and stimulants (3.9%).  78.2% reported that the drug was prescribed by a doctor 
for their use.  Of course, these prescription drugs may cause impairment even when taken as 
prescribed by a doctor.  While medication labels caution patients not to drive or operate 
machinery until they know how the drug will affect them, it is well established that people are 
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poor judges of their own level of impairment (Brumback et al. 2007, Echizenya et al. 2007).  For 
drugs that may cause impairment the day after ingestion, there may be even greater risk that the 
person will be unaware of their own degree of impairment.  The most common prescription 
medications detected during autopsy of fatally injured drivers for the past 10 years are listed in 
Table 1.4.  Notably, alprazolam is in the top three most commonly detected drugs in fatally 
injured drivers for 8 of the past 10 years.  In some cases, patients may be unaware of their own 
degree of impairment after use of a prescription medication, and the impairment can be 
significant.  In the case of zolpidem, a sleeping medication, the impairment caused by its use was 
of significant scope and severity that the FDA required a labeling change to reduce starting doses 
for women (FDA 2013a) in 2013. 
 
Zolpidem:  Zolpidem is an imidazopyridine non-benzodiazepine hypnotic indicated for short-term 
treatment of insomnia; specifically, for insomnia characterized by difficulty falling asleep.  It was 
approved by the FDA in 1992, and a controlled-release formulations was later approved for 
insomnia characterized by difficulty staying asleep (Sanofi-Aventis 2005).  At the time of 
approval, the adult starting dose for immediate-release (IR) zolpidem was 10mg.  Zolpidem is 
structurally similar to the benzodiazepines (see Figure1.1) and binds to the benzodiazepine site on 
GABAA receptors, but zolpidem exerts mostly hypnotic effects (as opposed to benzodiazepines 
which have hypnotic, anxiolytic, amnesiac, and anticonvulsant effects).   It has specificity for the 
α1 subunit-containing GABAA receptors, low affinity for α2 and α3 subunit-containing receptors, 
and negligible affinity for the α5 subunit-containing receptors (Crestani et al. 2000).  This subunit 
specificity is thought to be the reason that zolpidem has poor anxiolytic and anticonvulsant 
properties compared to the benzodiazepines which have equal affinity for all receptor subtypes 
(Hanson et al. 2008).  Zolpidem is administered immediately before bed, and causes significant 
sedation as well as cognitive, psychomotor, and memory impairment within 15min of 
administration.  The immediate-release (IR) zolpidem formulation has a reported half-life of 2-
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3hr (Sanofi-Aventis 2014), and the duration of action was originally reported to be 3hr; meaning 
that persons using zolpidem before bed and getting a full night of sleep should no longer exhibit 
impairment upon waking.  Post-marketing surveillance revealed that this was not the case.  From 
2007 to 2013, the FDA received approximately 700 reports, submitted to the Adverse Event 
Reporting System, of driving impairment and traffic accidents linked to previous day use of 
zolpidem (FDA 2013b).  
 
These reports were substantiated by driving simulation studies and pharmacokinetic analyses 
conducted the morning after zolpidem administration.  Leufkens and colleagues performed 
psychomotor performance evaluations using an on-the-road driving task and several classical 
cognitive and psychomotor tasks to assess impairment the morning after administration of 
multiple hypnotic agents, including zolpidem.  They report that 10 – 11hr after 10mg zolpidem 
administration, driving performance was significantly impaired.  The next-day impairment was 
not limited to driving: zolpidem administration also caused significant impairment in the critical 
tracking test, the divided attention task, the Digit Symbol Substitution Test, as well as significant 
increases in body sway compared to placebo (Leufkens et al. 2009).  Although the studies that the 
FDA used to link zolpidem blood concentrations to impairment levels are not publically 
available, press releases state that 15% of women and 3% of men had blood concentrations above 
50 ng/mL (the concentration determined by the FDA to correlate with significant impairment) 8hr 
after administration of 10mg IR zolpidem products (FDA 2013c).  The percentage of persons 
exceeding the 50ng/mL threshold 8hr after ingestion of CR zolpidem products was 25% and 33% 
for men and women, respectively (FDA 2013c) but the vast majority (i.e., 90%) of zolpidem 
prescriptions dispensed are for the IR formulations.  With ~40 million zolpidem prescriptions 
dispensed in 2011 , a conservative estimate of the possible number of impaired drivers on the 
road that year exceeds 400,000 (assuming all prescriptions were for 12 months and an equal 
gender split in prescribing), presenting a serious threat to public safety.  Importantly, body weight 
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did not completely account for the sex differences in pharmacokinetics (FDA 2013c), which are 
thought to be due in part to reduced clearance processes in women compared to men.  In a study 
comparing IR zolpidem pharmacokinetic parameters between men and women in Asian 
populations (Guo et al. 2014), maximum plasma concentration (male: 169.11 μg/L vs. female: 
217.83 μg/L), half-life (male: 0.94 hr vs. female: 0.79 hr), volume of distribution (male: 66.59 L 
vs. female: 47.50 L), clearance (male: 27.51 L/hr vs. female: 13.58 L/hr), and area-under-the-
curve (male: 507.86 μg*hr/L vs. female: 784.20 μg*hr/L) parameters were all significantly 
different between sexes after controlling for weight.  The direction of these pharmacokinetic 
differences all support the increased duration of impairment experienced by women than men.  
 
From 1992 to 2013, the recommended dose of IR zolpidem for all adults was 10mg to be taken 
before bedtime.  Based on driving and pharmacokinetic data, the FDA required labeling changes 
to all IR zolpidem-containing products to reduce the starting dose for women to 5mg in 2013.  No 
changes were made to the CR zolpidem product doses.  In addition to the new IR dosing 
recommendations, zolpidem-containing drug labels now have stronger warnings about the risks of 
next-day impairment.  Specifically, driving or engaging in any task requiring mental alertness is 
cautioned against if: zolpidem is taken with less than a full night’s sleep remaining; if a higher 
than recommended dose is taken; if co-administered with other CNS depressants; or if co-
administered with drugs that could increase blood levels of zolpidem.  These include CYP3A4 
inhibitors such as ketoconazole, amiodarone, and fluconazole.  Patients should be cautioned that 
they might be impaired even if they feel awake.  There is a need for accurate and thorough 
labeling to inform patients and prescribers of potential risks, side effects, and duration of possible 
impairment for each medication.  Medications with characteristics similar to zolpidem may also 
cause previously unknown cognitive or psychomotor impairment the morning after ingestion, and 
may present dangers to public health and safety.  
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PART II.  Legislation and Measurement of Impaired Driving 
It is illegal in the United States to drive under the influence of impairing amounts of alcohol or 
other drugs, but defining “impairing amounts” of drugs (including prescription and over-the-
counter medications) presents a unique challenge compared to such a definition for alcohol.  
Nevertheless, it is important to understand how and why the current drunk driving laws were 
instituted so that law enforcement, legislators, and other stakeholders can learn from, and improve 
on, the current system.  
 
Historical Context and Evidence Supporting Current Drunk Driving Legislation 
Breath alcohol can be quickly, easily, and inexpensively measured at the scene of an accident or 
traffic stop, allowing law enforcement to ascertain whether a driver has a BAC at or above the 
established illegal level of .08%.  Importantly, it illegal in and of itself to operate a motor vehicle 
with an alcohol concentration measured at or above the established illegal level, regardless of 
whether or not the driver exhibits visible signs of intoxication.  This .08% BAC per se limit was 
not accepted by all states until 2004.  Before that time, laws varied between states; and as recently 
as 2001, the states were evenly split between establishing the legal limit as .08% or .10% BAC.  
Ultimate adoption of the .08% limit by all states was largely due to financial incentives from the 
federal government; the Department of Transportation's 2001 Appropriations Act (HR4475) 
provided that states must pass a .08% per se law by 2004 or begin losing federal highway 
construction funds (2% penalty, with the penalty increasing by 2% each year, until reaching 8%; 
representing a significant amount of funding – as an illustrative example, the last state to adopt 
this policy, Delaware, would have forfeited ~3.3 million dollars in 2004).  
 
The support for establishment of a .08% BAC per se legal limit originated from laboratory and 
epidemiological evidence.  A review of 112 laboratory studies determined that at .08 BAC, 
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virtually all (94%) persons exhibit substantial impairment in driving-related skills such as 
braking, steering, lane changing, judgment and divided attention (Moskowitz and Fioreninto 
2000).  An analysis of traffic fatalities in five states (CA, ME, OR, UT, VT) before and for at 
least two years after implementation of state-mandated .08% BAC per se laws reported that there 
were significant decreases in alcohol related crashes (ranging from a 4 percent decrease in the 
level of driver involvement in alcohol related fatal crashes at .10% BAC to a 40% decrease in the 
level of driver involvement in fatal crashes estimated to be alcohol involved) after adoption of the 
.08% BAC limit (Johnson and Fell 1994).  Likewise, a review of seven retrospective case-control 
studies comparing BAC between drivers involved in crashes and those not involved in crashes 
concluded that there was some increase in relative crash risk between 0.00% and 0.05% (the 
estimates of relative risk for drivers with a positive BAC less than .05% are less than or equal to 
1.5 times the risk of drivers with a 0.00% BAC), followed by a more rapid increase in relative 
risk around 0.08% to 0.10% (between 2 and 20 times the risk of drivers with a 0.00% BAC) 
(NHTSA 1991).  Based on epidemiological and experimental evidence, a blood alcohol 
concentration above 0.08% is considered to be significantly impairing, and it is therefore illegal 
to drive with concentrations exceeding 0.08%.  For drugs and medications, the evidence linking 
blood concentrations to crash risk are less robust.  
 
 
Implementing Drugged Driving Legislation 
Defining a blood concentration at which there is a reasonable expectation of impairment for every 
drug and medication is both impracticable and of questionable utility.  There have been three 
general strategies employed for drugged driving legislation: zero-tolerance policies, defining 
legal limits for blood concentration of certain drugs, and no legal limit (but law enforcement may 
test a driver suspected of drug-induced impairment and charge them with a DUI if the result is 
positive).  The zero-tolerance policy enacted by some countries (e.g., Italy) and 16 states 
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mandates that driving with any detectable trace of a designated impairing substance (including 
opioids and benzodiazepines) is against the law; meaning that a positive drug test for an illegal 
drug such as marijuana or a prescription drug such as oxycodone would have similar legal 
repercussions for the driver, such as fines, license revocation, and/or jail time (Ferreira 2007).   In 
places that have imposed legal limits for specific drugs based on concentrations estimated to be 
impairing, there is not a consensus threshold.  Even for marijuana—the most commonly used 
impairing substance after alcohol—the laws vary widely between states (GHSA 2017).  Montana 
and Washington have per se limits for THC concentrations above 5ng/mL, and Colorado law 
considers there to be a reasonable inference of impairment at THC concentrations above 5ng/mL.  
The limits are different for Nevada, Ohio (2ng/mL) and Pennsylvania (1ng/mL).  Moreover, laws 
vary on legal limits of metabolites.  The third strategy, employed by 28 states, relies on a driver’s 
judgement to not drive if impaired.  Individual tolerance (see above section for details) can vary 
significantly from one person to the next (e.g., after use of a therapeutic dose of oxycodone 
[30mg], a person who chronically uses opioids at or above that dose would almost certainly be 
less impaired than a person who has used opioids only a few times).  If a law enforcement officer 
suspects a driver of impairment, a breath alcohol test and/or field sobriety test is typically 
administered, and law enforcement officials may also require a drug test in cases of suspected 
drug-related impaired driving.  If the test is positive for a drug, regardless of the concentration, 
the driver could be charged with driving under the influence.  
 
Ideally, whatever legislative strategy is employed would be evidence-based.  Accurate data are 
needed to determine which drugs cause impairment and the expected profile of that impairment.  
These data would support both legislative decisions and appropriate warnings on medication 
labels.  However, determining which drugs cause impairment and fully characterizing the time-
course and severity of that impairment is methodologically challenging.  The first step in 
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determining which drugs impair driving would be to define what constitutes meaningful driving 
impairment.  
 
 
Methods for Determining Meaningful Driving Impairment and Elevated Crash Risk after 
Use of a Potentially Impairing Substance 
An expert panel of behavioral scientists, epidemiologists, pharmacologists, toxicologists, and 
traffic safety professionals was convened by NHTSA in 2008 and 2009 in order to determine if it 
was feasible to develop two lists: one list of medications or classes of medications that may 
impair driving and a second list of medications that do not impair driving (Kay and Logan 2011).  
These lists could be used to inform both prescribers and patients about the likelihood of impaired 
driving due to use of the constituent medications.  The expert panel concluded that the absence of 
a standardized protocol for assessing the impairment potential of drugs was a serious barrier to 
categorization based on impairment risk.  For the few drugs that had extensive behavioral testing 
completed, assessing driving impairment risk based on extant literature remained difficult due to 
the inconsistency in testing methodologies used.  Factors that vary widely from one research 
protocol to another (even for evaluation of the same drug) included elements such as: dose range, 
interval between dosing and assessment, interaction between drug and condition being treated 
(i.e., study population made up of patients or non-patients), chronicity of use, and inclusion of 
appropriate positive and negative controls.  Based on review of existing behavioral assessment 
protocols and scientific literature, the panel concluded that a tiered, parallel process involving 
pharmacological, toxicological, epidemiological reviews and a standardized behavioral 
assessment (based on the Essential Driving Ability Domains model) would provide the most 
comprehensive evaluation of driving impairment and risk.  Notably, the FDA also recommends 
this tiered multi-modal approach to assessing driving impairment risk (FDA 2015). 
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The Essential Driving Ability Domains (EDAD) model suggests that the following five 
behavioral domains are relevant to driving ability: 1) alertness/arousal, 2) attention and 
processing speed, 3) reaction time/psychomotor functions, 4) sensory-perceptual functions, and 5) 
executive functions.  Alertness/arousal refers to the person’s degree of consciousness.  
Drowsiness (or lack of alertness/arousal) is associated with increased standard deviation of lane 
position and speed—two driving outcomes positively associated with crash risk (Verster and 
Mets 2009, Penning et al. 2010).  The panel concluded that any drug causing impairment in 
performance in any of these five domains at a magnitude known to be associated with increased 
crash risk is presumed to have a negative impact on driving safety.  As technology has evolved, 
so have the methods available for assessing driving performance.   
 
Simple laboratory measures:  Older measures of cognitive and psychomotor impairment include 
tasks such as the Digit Symbol Substitution Task, Choice Reaction Time, Critical Flicker Fusion 
Task, Balance Test, etc.  These simple tasks are easy to administer, quick, and relatively 
inexpensive, but they can only capture one facet of behavior required by an action as complex as 
driving.  Moreover, it is not clear how well each assessment (or even a battery of these 
assessments) maps on to driving ability.  In one study comparing several psychometric tasks to 
on-the-road driving, it was reported that results from each of the psychometric tasks (tracking, 
divided attention, reaction time, Critical Flicker Fusion Test, memory, and tapping) individually 
had low to modest correlations (r = 0.2 to 0.4) to SDLP (Ramaekers 2003).  Because each of 
these psychometric tests assesses separate skills and abilities (e.g., alertness, attention, reaction 
time, etc.) that are thought to be important to driving ability (ICADTS), the results from a 
combination of these tasks may provide greater correlation to SDLP.  Verster and Roth analyzed 
results from a battery of seven psychometric tasks compared to SDLP and still found that the 
tasks together had a predictive validity of only 33.4% for on-the-road driving (Verster and Roth 
2012a).   
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On-the-road driving task:  On-the-road driving assessment is the gold standard methodology of 
driving impairment research as it almost exactly mimics the real world.  The test is performed in 
normal traffic on a 100km stretch of a public highway.  Because traffic is present, participants 
have to react to other cars, and unexpected circumstances and events (e.g., traffic jams, 
emergency stops, etc.).  Participants are instructed to drive with a steady lateral position within 
the right lane and to maintain a constant speed of 95 km/hr.  They are allowed to pass slower-
moving vehicles, but otherwise are to maintain the indicated course and speed.  A trained 
instructor with override pedals and steering is in the passenger seat in the event that the 
participant is too impaired to safely operate the vehicle.  The car is outfitted with specialized 
machinery to track the lateral movement (i.e., “weaving”) of the car, and the primary outcome 
measure is standard deviation of lane position (SDLP).  These tests have superior external 
validity but are costly, time-consuming, and require specialized equipment and highly trained 
staff to administer.  While no traffic accidents have occurred in the 30-year history of these 
experiments (Verster and Roth 2011), safety concerns may preclude the examination of extremely 
impairing doses of alcohol or drugs.  As seen in Table 1.7, the highest dose of alcohol tested in 
these on-the-road driving studies is ~.10% BAC.  
 
Driving simulator task:  The third method that is commonly used to assess driving performance is 
with a computerized driving simulator, which obviates any safety concerns inherent to allowing 
potentially impaired persons driving a vehicle in traffic.  This allows for testing of higher doses of 
alcohol and more impairing drugs than on-the-road driving tasks.  There is a range of driving 
simulator systems available, ranging from simple, single-screen systems on one end of the 
spectrum to high fidelity and immersive systems on the other.  The most basic systems consist of 
a single computer screen mounted directly in front of the volunteer, a gas and brake pedal and 
steering wheel.  The most complex simulators (i.e., National Advanced Driving Simulator-1) 
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consist of an actual car mounted on a movable base to mimic turning, pitch, and vibration from 
different road surfaces.  The car is housed within a dome, and 360-degree scenery is projected on 
the inside of the dome.  While this complex system eliminates the safety concerns inherent to on-
the-road driving assessment of drug-impaired participants, it is still quite costly and requires 
highly technically proficient staff for daily operations and maintenance.  There are many other 
systems with intermediate complexity.  The more immersive and realistic the system is, the more 
generalizable the results should be to real-world driving.  
 
Use of a driving simulator allows for standardized and reproducible testing of the operational and 
tactical aspects of driving.  Every detail of the driving experience is customizable: investigators 
can select road surface, visibility, traffic conditions, vehicle type, scenery, time of day, etc.  
Unlike on-the-road tests in which real-world weather and traffic conditions will vary, the driving 
simulator ensures that these (and thousands of other) variables are identical every time the driving 
task is completed.  Of course, this customizability and range of options means that no two 
research groups have identical driving tasks.  Simulators are capable of capturing thousands of 
data points per second; thus, the outcomes and possibilities for data analysis are almost endless.  
Some commonly used tasks and outcomes are described below.  
 
Car following:  In this task, participants are instructed to follow a lead car at a safe 
distance.  The lead car can be programmed to randomly change speed (e.g., (Brookhuis et al. 
1994)) or maintain a constant speed (e.g., Kenntner-Mabiabla et al. 2015).  Outcome measures for 
this task include gap (distance between the front bumper of the volunteer’s car and the rear 
bumper of the lead car), minimum time-to-collision, and coherence (i.e., the extent to which the 
patterns of speed changes of the lead- and following car are the same).  
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Gap acceptance:  This task is used to measure risk-taking behavior (e.g., Fillmore et al. 
2005; Fillmore et al. 2008).  Though there are variations in task specifics; generally, the 
participant must make a turn into traffic that has the right-of-way.  The time between each of the 
oncoming vehicles range from 1sec to 12sec, so the driver must consider the waiting time versus 
the risk of causing an accident.  Shorter gap time is indicative of riskier behavior. 
 
Incursion:  This task assesses reaction time and alertness.  A vehicle, pedestrian, or other 
object moves into the participant’s lane, requiring them to either brake or steer to avoid a 
collision with the object.  Outcomes include minimum time-to-collision and reaction time.  
 
Speed tracking:  It has been demonstrated that participants will vary speed in order to 
compensate for sedating effects or because perception of risk is decreased (e.g., (Brookhuis et al. 
2004)).  In an attempt to increase arousal, sedated participants will temporarily increase their 
speed.  Over the course of a driving scenario, this results in a more variable standard deviation of 
speed compared to non-sedated drivers (Brookhuis 1998).  
 
Lane tracking/Standard deviation of lane position (SDLP):  For both on-the-road driving 
and computerized driving simulator tests, the primary outcome measure reported is almost 
exclusively SDLP (i.e., a measure of weaving).  Larger SDLP is associated with increased crash 
risk (O'Hanlon 1984, Verster and Mets 2009, Penning et al. 2010).  Table 1.5 displays the SDLP 
results from 16 cross-over design studies in which healthy volunteers received placebo and 
alcohol in different sessions.  Results are displayed from studies using on-the-road driving and 
driving simulator tasks.  Breath alcohol concentrations of 0.05% and 0.08% are considered 
meaningful benchmarks because 0.05% is the legal limit in most of the countries in the European 
Union and 0.08% BAC is the legal limit in the United States.  Epidemiological data on the 
correlation between BAC and accident risk revealed that crash risk increases at a blood alcohol 
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concentration of 0.04% and exponentially rises above 0.10% (Borkenstein 1978).  Drugs that 
cause an increase in SDLP equivalent to what is observed with a breath alcohol concentration of 
.05% or .08% could be considered significantly impairing.  
 
Importantly, absolute SDLP values are not reliable predictors of impairment seen after drug or 
alcohol administration because individual differences in SDLP are large.  Instead, calculating 
SDLP changes from placebo to the active condition is the preferred method of determining drug- 
or alcohol-induced impairment.  This is the case because group-level SDLP changes are stable 
and independent of the magnitude of baseline or placebo SDLP values.  For these reasons; when 
conducting a drugged driving study with either the on-the-road or driving simulator task, it is 
imperative that the study utilizes a within-subject, repeated measures design.  Landmark work 
conducted by Louwerens and colleagues calibrated ascending BACs (group BAC means: 0.024%, 
0.06%, 0.085%, and 0.122%) with changes in SDLP in 24 healthy volunteers participating in an 
on-the-road driving test.  The group mean increases in SDLP from placebo to BACs .05% and 
.08% were 2.4 cm and 4.1 cm, respectively (Louwerens et al. 1987).  These numbers have since 
been used as benchmarks of impairment in over 50 on-the-road driving studies, and the results 
have been corroborated in other on-the-road driving studies with placebo and similar alcohol 
administration conditions (see Table 1.7).  Owens and Ramaekers found a very high correlation (r 
= 0.99) between SDLP increases at ascending BACs and epidemiological studies relating BAC 
and accident data (Owens and Ramaekers 2009).  Although direct data relating change in SDLP 
to accidents are lacking, these correlative data support the utility of SDLP measurements in its 
relationship to crash risk.   
 
Because on-the-road driving tests and driving simulator tasks are both used so frequently in 
drugged-driving research, it is important to compare SDLP outcomes between these two methods 
to ensure that the impairment benchmarks used for on-the-road driving tests are also well-suited 
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for simulator studies.  While a review of the literature reveals no studies that compare SDLP 
outcomes derived from on-the-road driving studies and driving simulator tasks in a within-subject 
design, Table 1.7 lists the group-level SDLP changes across 16 studies (both on-the-road and 
simulator).  From these studies, it is clear that, at least for the SDLP changes from placebo to 
BACs of .05% and .08%, on-the-road and simulator tasks are strikingly comparable.  The average 
SDLP changes for on-the-road vs. simulator tasks differ little at BAC .05% (2.0cm and 2.1cm) 
and at BAC 0.08% (4.1cm and 4.1cm).  
 
PART III.  Multi-Modal Evidence of Alprazolam-induced Driving Impairment  
 
General Background and Prescription Rates  
Alprazolam is a triazolo benzodiazepine indicated for the treatment of panic and anxiety 
disorders.  It was first approved in the U.S. in 1981 for panic disorder and an extended-release 
(ER) formulation was subsequently approved in 2003.  Alprazolam has consistently been one of 
the most frequently prescribed psychiatric drugs in the U.S.  Data from IMS Health show that it 
was the most frequently prescribed psychiatric drug in 2005, 2009, 2011 & 2013—most recently 
in 2013, with a record ~48.5 million prescriptions written.  Although more recent data for the 
number of alprazolam prescriptions written are not publically available, alprazolam was still the 
second most-prescribed psychiatric medication in 2016 (Grohol 2017).   
 
While only five benzodiazepines are FDA-approved for insomnia (i.e., flurazepam, temazepam, 
triazolam, estazolam, and quazepam), these older benzodiazepines are no longer commonly 
prescribed; instead, doctors now more commonly prescribe benzodiazepines such as diazepam, 
alprazolam, lorazepam, and clonazepam for sleep disturbances, particularly in patients with mood 
or anxiety disorders (Lader 2011).  Although these newer benzodiazepines are not indicated for 
sleep disturbances, off-label prescribing (i.e., prescribing currently available and marketed 
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medications for an indication that has not received FDA approval) is legal and common.  An 
estimated 1 in 5 prescriptions are written for off-label use (AHRQ 2015).  Benzodiazepines are 
prescribed to women almost twice as often as to men (Olfson et al. 2015) and in 2013, an 
estimated 5.6% of the adult U.S. population filled a benzodiazepine prescription in the past year 
(Bachhuber et al. 2016).  
 
Pharmacology/Toxicology  
Alprazolam is a 1,4-triazolobenzodiazepine analog that differs in structure from classical 
benzodiazepines, such as diazepam, by the presence of a triazole ring (see Figure 1.1).  The 
addition of the triazole ring to the diazepine scaffold promotes activity at different receptor 
subtypes than benzodiazepines with a carbonyl or other functional groups.  Like other 
benzodiazepines, alprazolam acts as a positive allosteric modulator of the gamma-amino butyric 
acidA (GABAA) receptor, a ligand-gated chloride-selective ion channel found on neurons.  GABA 
is the primary inhibitory neurotransmitter in the central nervous system, and it binds to 
approximately 30% of all brain synapses—resulting in widespread and non-specific inhibitory 
effects.  Each GABAA receptor complex is made up of five glycoprotein subunits (two α 
subunits, two β subunits, and one γ subunit) and contains three binding sites (two GABA binding 
sites [(Macdonald and Olsen 1994)] and one benzodiazepine binding site).  Benzodiazepines 
enhance the activity of GABA in two ways: by increasing the probability that GABA will bind to 
its receptor and by amplifying the magnitude of effect after GABA is bound.  When 
benzodiazepines bind to their binding site in the pocket between the α and γ subunits, it induces a 
conformational change that increases the affinity of the GABA binding site for GABA.  Once 
GABA is bound to its receptor, it causes hyperpolarization of the neuronal cell via chloride influx 
and subsequent inhibition of action potentials.  Additionally, electrophysiological studies have 
demonstrated that benzodiazepines increase the frequency of chloride channel opening in 
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response to GABA binding, providing another mechanism of hyperpolarization and inhibition of 
cellular activity (Gallager et al. 1984, Smith and Gallager 1987).  
 
Multiple types of benzodiazepine receptors exist; they are classified by the isoform of the 
GABAA receptor α subunit on which the benzodiazepine binding pocket is found and by their 
clinical effect.  The differences in receptor subtypes and the way ligands interact with different 
residues in the benzodiazepine binding site are important considerations for drug development, as 
researchers aim to exploit these differences to develop selective drugs with improved specificity 
and reduced off-target effects (McKernan et al. 2000, Atack 2005, Skolnick 2012).  Because of 
the numerous and varied interactions between ligands and receptor, drugs that interact with the 
benzodiazepine binding site can be anxiolytics, hypnotics, or myorelaxants (Sternbach 1979, 
Villar et al. 1991, McKernan et al. 2000), though overlapping effects among these drugs is 
common.  The two benzodiazepine receptor types about which the most is known are types 1 and 
2.  The benzodiazepine-1 receptor contains the α1 subunit, is present in 60% of all GABAA 
receptors, and is highly concentrated in the cortex, thalamus, and cerebellum.  Binding of this 
receptor subtype is thought to be responsible for the sedative, anticonvulsant, and amnesic effects 
of benzodiazepines.  The benzodiazepine-2 receptor contains the α2 subunit, is present in an 
unknown percentage of all GABAA receptors, and is highly concentrated in the limbic system, on 
motor neurons, and the dorsal horn of the spinal cord.  It is thought to mediate the anxiolytic and 
myorelaxant properties of benzodiazepines.  
 
Approximately 90% of alprazolam is absorbed from the digestive tract after oral administration, 
and rate of absorption is dose-independent (Greenblatt et al. 1993), meaning that peak 
concentrations are not achieved sooner after larger doses.  There is no evidence for metabolic 
tolerance to benzodiazepines after repeated exposure (in contrast to what is observed after chronic 
alcohol administration).  In patients with panic disorder either chronically using alprazolam or not 
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being treated with benzodiazepines, plasma concentrations after acute diazepam administration 
did not differ between groups (Cowley et al. 1995).  Metabolism of alprazolam occurs by hepatic 
microsomal oxidation and is mediated by cytochrome P4503A4.  While 29 metabolites of 
alprazolam have been identified, none are considered to significantly contribute to its clinical 
effects.  The two primary metabolites of alprazolam, 4-hydroxy alprazolam and α-hydroxy 
alprazolam, are present at low concentrations (i.e., concentrations of less than 0.04 those of parent 
drug) and show significantly reduced benzodiazepine receptor affinity (between 0.20 and 0.66) 
compared to alprazolam itself (Pfizer 2011).  Alprazolam is highly protein bound.  It is widely 
distributed in the body, easily crosses the blood-brain barrier, and preferentially accumulates in 
lipid-rich areas, such as the central nervous system and adipose tissue.  The elimination half-life 
is estimated to be 6 to 27hr, and approximately 80% of alprazolam is excreted unchanged by the 
kidney.  The estimated half-life is similar for both the immediate-release (IR) and extended-
release (ER) formulations (~11hr and 10.7—15.5hr, respectively) (Pfizer 2011, Pharmacia and 
Upjohn 2011).  The pharmacological actions described above are responsible for the clinical and 
behavioral effects of alprazolam.   
 
Behavioral Effects of Alprazolam 
Numerous laboratory studies report that acute benzodiazepine exposure causes cognitive and 
psychomotor impairment (see, for example, (Evans et al. 1994, Verster et al. 2002b, Stewart 
2005)).  Single-dose behavioral studies in healthy volunteers have administered alprazolam doses 
of 0.25 to 2.0mg, and generally report that acute alprazolam administration results in dose-related 
decrements in task performance (Verster and Volkerts 2004).  In non-patient populations, acute 
impairment due to alprazolam administration is evident across a wide range of tasks commonly 
used in psychopharmacology research, including the Digit Symbol Substitution Task [DSST: e.g., 
(Ellinwood et al. 1985, Fleishaker et al. 1995)], Card Sorting Task [e.g., (Ellinwood et al. 1987)], 
Critical Flicker Fusion Test [CFFT: e.g., (Subhan et al. 1986)], vigilance [e.g., (Kozena et al. 
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1995)], reaction time [e.g., (Crombez et al. 1991)], and mental recall [e.g., (Barbee et al. 1991)] 
tests.  Alprazolam-induced impairment in healthy volunteers has also been demonstrated during 
an on-the-road driving task performed 1hr after 1mg alprazolam administration compared to 
placebo (Verster et al. 2002b).  When administered chronically (i.e., one week or longer) to 
healthy volunteers, alprazolam causes little significant psychomotor and/or cognitive impairment 
(Aranko et al. 1985, Allen et al. 1991, Hart et al. 1991, Bourin et al. 1998) as measured by the 
same tasks that showed significant impairment after single dose studies (e.g., DSST, CFFT).  
Likewise, patients with panic disorder using alprazolam chronically displayed no increase in 
sedation or motor impairment after the acute alprazolam administration (Cowley et al. 1995).  In 
these repeated dosing studies, the tasks are completed at baseline and then repeated under placebo 
or chronic alprazolam administration conditions; thus, a practice effect may explain 
improvements in participant performance.  The other likely explanation is that participants and 
patients became tolerant of alprazolam effects.  
 
It is well-known that tolerance develops to some of the therapeutic effects of benzodiazepines, 
thereby limiting their use for some indications.  Benzodiazepine use in epilepsy is limited in part 
due to the development of tolerance to their anticonvulsant effects (Browne and Penry 1973, 
Isojarvi and Tokola 1998).  Anxiolytic tolerance develops slowly in patient populations.  After 8 
weeks of alprazolam treatment, patients with panic disorder did not display anxiolytic tolerance 
(i.e., their ratings of alprazolam efficacy remained high), nor did they require dose increases (a 
hallmark of tolerance development) (Schweizer et al. 1993).  Similar results have been found for 
long-term alprazolam anxiolytic efficacy for patients with generalized anxiety disorder (Cohn and 
Wilcox 1984).  GABAergic activity underlies the cognitive and psychomotor impairment seen 
after alprazolam administration, and this impairment may have a role in traffic accidents. 
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Epidemiology of Driving Impairment and Crash Risk from Benzodiazepines Including 
Alprazolam  
Epidemiological studies consistently report that benzodiazepine use correlates with driving 
impairment.  One observational study looking at benzodiazepine concentrations in the bodily 
fluids of drivers arrested for reckless driving reported higher blood concentrations in more 
impaired drivers (Bramness et al. 2002).  A meta-analysis of published epidemiological studies 
determined that drivers with benzodiazepine prescriptions were at 60 – 80% greater risk of traffic 
accidents and were 40% more likely to be the party responsible for the accident (Dassanayake et 
al. 2011).  Risk of traffic accidents may be highest for those recently prescribed benzodiazepines.  
Using the Saskatchewan Health database information (which includes prescription information 
and hospital admissions for over 98% of the population), 148,000 adults with an anxiolytic 
benzodiazepine prescription (and 98,000 age and sex-matched controls) were identified and 
monitored for traffic-accident-related hospitalization for two months after the first prescription 
fill date (Neutel 1995).  Risk of hospitalization for a traffic-accident-related condition was highest 
within one week of benzodiazepine prescription (OR = 13.5) and remained elevated when the 
timeframe examined extended to two weeks (OR = 5.6) and four weeks (OR = 2.5) of 
benzodiazepine prescription.  Oster and colleagues likewise used insurance claim data to assess 
traffic accident and injury rates in 7,271 persons prescribed an anxiolytic benzodiazepine 
compared to 65,439 controls and found that a significantly higher percentage of those prescribed 
benzodiazepines needed medical attention and hospitalization than controls (Oster et al. 1987).  
Perhaps the most compelling data would be those describing risk of traffic accidents before and 
after benzodiazepine prescription initiation in the same persons; unfortunately, only one study of 
this type could be found.  Oster and colleagues (Oster et al. 1990) examined traffic-accident-
related injury three months before and for six months after initial anxiolytic benzodiazepine 
prescription in 4,554 persons.  Post-prescription initiation risk of traffic-accident-related injury 
was increased compared to the three months before prescription initiation (OR = 1.15).  Notably, 
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when compared to a group of 13,662 controls, the future benzodiazepine users were more likely 
to require medical attention for a traffic-accident-related injury (OR = 1.5), suggesting that 
anxiety may by itself increase the risk of traffic accidents.   Using prescription databases to 
follow drivers in the United Kingdom, Barbone and colleagues reported that drivers using 
benzodiazepines on the day of the accident were at higher risk of being involved in a traffic 
accident (odds ratio [OR] 1.63) compared to drivers without reported benzodiazepine use.  The 
odds of crash risk were higher for benzodiazepines than for selective serotonin-reuptake 
inhibitors (OR = 0.85), tricyclic antidepressants (OR = 0.93) or 47 other psychoactive drugs (OR 
= 0.88) and crash risk was higher for anxiolytic benzodiazepines with long half-lives (OR = 2.22) 
than intermediate half-lives (OR = 1.59) (Barbone et al. 1998).  
 
Time course of alprazolam effects:  From the previous sections, it is clear that benzodiazepines in 
general, and alprazolam specifically, cause acute cognitive and psychomotor impairment in both 
preclinical and clinical populations as measured by a multitude of assessment methodologies.  
Extant literature does not; however, adequately describe the complete time course of alprazolam 
impairment.  As is common in psychopharmacology research, the outcome measures reported 
were from the expected time of peak effects, but because alprazolam possesses a long half-life 
(~11hr), it could be expected that deleterious effects on cognition, reaction time, processing 
speed, and psychomotor performance could still be present long after peak effects are exhibited. 
This hypothesis has indirect support in the literature from a few studies but has not been directly 
investigated.  
 
The sedating effects of alprazolam display a counter-clockwise hysteresis (i.e., Emax [maximum 
drug effect] occurs after Cmax), which may have clinically significant implications.  Smith and 
Kroboth (Smith and Kroboth 1987) determined that the peak sedating effect of a single 
alprazolam dose occurred four hours after Cmax was reached.  This lag between Cmax and Emax 
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was still present after 4 days of twice-daily alprazolam dosing and may be due to delayed drug 
entry into the central nervous system.  Alprazolam Cmax is reached ~2hr after oral 
administration, suggesting that sedative effects may be greatest around 6hr after administration. 
 
A small trial evaluated reaction time and critical flicker fusion, a measure of visual persistence, 1 
and 11hr after 2mg nighttime alprazolam or placebo administration.  At both measurement times, 
choice reaction time was impaired after the alprazolam condition compared to placebo.  The 
critical flicker fusion scores were also slower following alprazolam at both 1 and 11hr, but this 
effect did not reach statistical significance (Norman et al. 1990).  A placebo-controlled trial 
assessing on-the-road driving ability 10-11hr and 16-17hr after nighttime administration of 
lormetazepam and flurazepam found that 2mg lormetazepam impaired driving performance 10-
11hr after administration (Brookhuis et al. 1990).  Importantly, lormetazepam possesses a half-
life comparable to alprazolam (i.e., 10-12hr) and is also metabolized via CYP3A4.  
 
Evidence from epidemiological surveys, laboratory studies and the pharmacology of alprazolam 
together suggest that alprazolam may indeed produce residual psychomotor effects the morning 
after nighttime use.  Those who use benzodiazepines at night for sleep or anxiety likely believe 
that the impairing effects would dissipate by the next morning; but, as was the case for zolpidem, 
this may not be true.  There are many important factors which may affect the profile of 
alprazolam impairment, but one important and often overlooked factor is sex. 
 
 
PART IV.  Sex Differences in Drug Response 
Sex differences in drug response can be extensive, but too often these differences are not 
examined during drug development and approval processes.  Since the 1938 establishment of the 
FDA until the end of 2017, 1,607 new molecular entities (i.e., new medications, not generics) 
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have survived the rigorous approval process to be designated as safe and effective for the 
treatment of a human disease (Kinch et al. 2014, Kinch 2015, FDA 2016, Griesenauer and Kinch 
2017, Kinch and Griesenauer 2018); however, over 1,000 of those medications were approved 
without ensuring that they were actually safe and effective for a demographic that comprises 50% 
of the U.S. population—namely, women.  This is due, in large part, to the fact that before 1993, 
“women of child-bearing potential” were prohibited in participating in many clinical trials.  Even 
after this rule was eliminated, men continued to comprise the majority of clinical trial participant 
populations.  Women participate in clinical trials about a third as often as men (Pinnow 2009), 
which is particularly problematic because women use prescription medications more frequently 
than men (Manteuffel et al. 2012).  The consequences of this disproportionate participation in the 
medication testing process have at times been dire.  Once medications are FDA-approved and on 
the market, sex differences in drug response can sometimes become readily apparent, and the 
FDA can appropriately require changes to indication or dosage or even remove dangerous drugs 
from the market.   
 
Causes of Sex Differences in Drug Response 
Many drugs removed from the market posed a greater danger to women than men (e.g., 
fenfluramine and terfenadine).  One common mechanism of this increased danger is in the form 
of drug-induced torsade de pointes, a potentially deadly form of ventricular tachycardia arising as 
a complication from long QT syndrome(Al-Khatib et al. 2003).  The underlying cause of the 
increased risk for drug-induced torsade de pointes and symptomatic long QT syndrome in women 
may be due to higher intrinsic heart rate, longer corrected QT interval and/or a shorter sinus nodal 
recovery time than men (Wolbrette et al. 2002).  Many drugs which prolong QT interval are still 
marketed (e.g., erythromycin, fluoxetine, quetiapine), but knowledge of the potentially fatal sex 
differences allows prescribers to make more informed risk/benefit calculations when dosing and 
prescribing these drugs to men and women (Roden 2004).  For medications that elicit less easily 
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measured (but not necessarily less hazardous) sex-specific consequences, the process of changing 
prescribing habits takes longer and often requires careful research to characterize those effects 
(e.g.,  as was the case for the 2013 sex-specific re-labeling of zolpidem, which had been on the 
market for over 20 years before it was discovered that zolpidem clearance was significantly 
slower in women than men, resulting in over-medication and a higher than expected incidence of 
adverse drug reactions in women using zolpidem-containing medications).  
 
In addition to physical differences (height, weight) between men and women, disparities in 
pharmacokinetic processes (i.e., absorption, distribution, metabolism, excretion) between men 
and women may contribute to sex differences in drug response.  Using a scintillation camera and 
computer to measure the rate of gastric emptying in 15 men and women after ingestion of a 
standardized radioactive-labeled meal, Datz and colleagues determined that women empty both 
solids and liquids from their stomachs significantly more slowly than men.  This difference in 
gastric emptying may contribute to sex-specific differences in drug absorption (Datz et al. 1987).   
Plasma binding protein levels can affect free vs. bound fraction of drug.  The volume of 
distribution for non-polar, lipid-soluble drugs (e.g., theophylline, chloroquine) is dependent on 
body fat percentage, which is typically higher in women than men (Anderson 2008).  Because 
adipose tissue is poorly vascularized and drug distribution is determined by perfusion, 
distribution for drugs that accumulate in adipose tissue is slow.  This drug sequestration in fat can 
result in extension of drug effects or elimination half-life (e.g., seen with repeated THC exposure 
[Ashton 2001]).  Several important plasma binding proteins (i.e., alpha-1 acid glycoprotein 
[AAG] and alpha globulins) are affected by estrogen (estrogen decreases AAG and increases 
globulin levels) (Soldin and Mattison 2009).  Blood flow has been shown to differ between men 
and women for certain organs/tissues (adipose M=5%, F=8.5%; heart M=4%, F=5%; kidney M = 
19%, F=17%; liver M=25%, F=27%; and muscle M = 17%, F =12%), affecting the rate of drug 
distribution, metabolism, and elimination (Soldin and Mattison 2009).  The activity of liver 
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cytochrome P450s may differ between men and women, and women can have slower drug 
clearance due to slower glomerular filtration rate (Greenblatt et al. 2000).   
 
Relative amounts of sex hormones may also influence drug effects—not only between men and 
women but also between women in different stages of the menstrual cycle (Spoletini et al. 2012).  
Use of oral contraceptives may even further complicate the characterization of sex-related 
differences in drug response (Ellinwood et al. 1984, Stoehr et al. 1984, Kroboth et al. 1985).  
Variations in any one of these pharmacokinetic factors can alter drug concentrations in the body, 
resulting in deviation from the expected range of effects.  This may manifest in several ways, 
such as women experiencing more adverse drug effects (Franconi et al. 2007); requiring different 
doses than men [e.g., in some cases of anesthesia (Pleym et al. 2003) and antipsychotics (Seeman 
2004)]; or unintentional drugged driving resulting in more accidents the morning after using a 
sedative medication (FDA 2013a).   
 
Sex Differences in Drugged Driving Research   
Little research has been conducted to describe potential sex differences in driving performance 
after administration of drugs.  Drugged driving studies have been typically conducted in females 
only [e.g., (O'Hanlon and Volkerts 1986)], in males only [e.g., (Volkerts et al. 1992)], or included 
both sexes but were not powered to detect sex differences [e.g., (Brookhuis et al. 1990, Hartman 
et al. 2015)].  Indeed, a 2012 review (Verster and Roth 2012b) of studies assessing driving 
performance after bedtime administration of sleeping medications found that only one of 14 
studies conducted a sex difference analysis (and importantly, found that women drove 
significantly worse than men the morning after middle-of-the-night zolpidem administration).  
Because of the dearth of studies analyzing sex differences in driving performance, the evidence 
for greater driving impairment in females than males after drug administration is sporadic.  In a 
pooled analysis of nine within-subject, blinded, placebo-controlled, on-the-road driving studies in 
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which a total of 148 (75 male) volunteers were administered placebo and alcohol before 
completing a driving task, Jongen and colleagues demonstrated that significant impairment (i.e., 
SDLP increase of 2.4 cm or greater) was displayed by 42.7% of males and 52.1% of females at a 
BAC of ~.05% compared to placebo (Jongen et al. 2017).  Other studies have reported no 
significant sex differences in driving simulator outcomes after zopiclone and ramelteon (Mets et 
al. 2011) and marijuana (Anderson et al. 2010), although SDLP was not assessed in the latter 
study.  
 
Sex Differences in Alprazolam Response 
Because alprazolam was approved before women were generally included in clinical trials, 
unknown sex differences in pharmacokinetics and/or pharmacodynamics may exist.  Indeed, 
alprazolam pharmacokinetic studies typically included only males (Ellinwood et al. 1985, Smith 
and Kroboth 1987, Wright et al. 1997); however, scattered evidence exists to support the presence 
of sex differences in response to alprazolam.  Alprazolam is a lipophilic drug (i.e., its volume of 
distribution depends on body fat percentage—which is typically higher in women).  Its 
mechanism of action is similar to that of zolpidem, a drug known to display sex-specific 
pharmacokinetics.  One study (Kirkwood et al. 1991) reported that women in the luteal phase 
reached higher peak alprazolam area-under-the-curve concentrations than women in the follicular 
phase; these concentrations also were higher compared to peak and area-under-the-curve 
concentrations in men.  The results were not statistically significant, but sample sizes were small 
(n = 3 - 4 per group) and only tested a single dose (1mg) of alprazolam.  Importantly, a study 
demonstrating that the peak sedating effect of a single alprazolam dose occurred 4hr after 
reaching peak alprazolam plasma concentration enrolled only males (Smith et al. 1984); 
therefore, it is unknown how sex-specific metabolic differences could affect the delay between 
peak plasma concentrations and peak effects.  Sex differences in pharmacokinetics have been 
reported for benzodiazepines as a class, if not for alprazolam specifically.  The elimination half-
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life of oxazepam has been demonstrated to be significantly longer in females than males and 
increases with age in females but not males (Greenblatt et al. 1980).  Women using oral 
contraceptives have also been reported to be more sensitive to the psychomotor effects of single 
doses of benzodiazepines than women not using oral contraceptives (Kroboth et al. 1985).  The 
potential pharmacokinetic and/or pharmacodynamic differences in alprazolam response between 
men and women are not fully characterized.  
 
 
PART V.  Summary 
Results from national surveys (both household and roadside) and alcohol/drug tests from drivers 
involved in fatal traffic accidents concur that while the prevalence of drunk driving has 
decreased, there has been an increase in persons driving under the influence of potentially 
impairing drugs (i.e., “drugged driving”).  Drugged driving is associated with significant 
mortality, both of the driver and of others on the road.  The most commonly detected drugs in 
drivers involved in a fatal accident include prescription medications (e.g., opioids and 
benzodiazepines), which may or may not have been used as directed by a doctor.  Even when 
used as directed, prescription medications can cause significant impairment that may be 
unbeknownst to the patient using them (or even to the doctors prescribing them).  More than 20 
years after its initial approval by the FDA, the sleeping medication, zolpidem, was discovered to 
produce significant impairment (resulting in elevated risk of involvement in traffic accidents) the 
morning after its use.  Despite having survived a rigorous pre-approval process, the time course 
of zolpidem effects was not completely characterized.  There may be other drugs with similar 
mechanisms of action for which the duration of effects is not fully elucidated.   
 
While the laws governing alcohol use and driving are standardized across the U.S. and are 
relatively simple to enforce, similar legislation for drug use is hampered by unique challenges 
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related to the definition and measurement of drugged driving.  Defining a blood concentration 
threshold for impairment (akin to a 0.08% BAC) for every possible drug is impractical; thus, 
there are laws which 1) define thresholds (of questionable scientific merit) for some drugs, 2) 
implement a zero-tolerance policy for all drugs, and 3) do not define any blood concentration 
thresholds but rely on police judgement of driver impairment.  Regardless of the legislative 
strategy ultimately used, it is important to accurately and completely inform patients of potential 
driving impairment (including the expected time course) caused by drugs prescribed to them so 
that they may be safe and in compliance with the law.  As exemplified in the 2013 case of 
zolpidem, it is clear that these data are not available for all prescription drugs currently on the 
market.  These data are also needed for drugs not yet approved.  Determining which drugs cause 
impairment and fully characterizing the time course and severity of that impairment is 
methodologically challenging.  
 
Measurement of drug effect on driving ability has historically been accomplished in one of three 
ways: with simple laboratory tasks, by using on-the-road driving tasks, or with a driving 
simulator.  The first method indirectly assesses some of the same skills ostensibly used for 
driving (e.g., reaction time, spatial awareness), but the external validity is low.  On-the-road 
driving tasks have obvious external validity, but their use is quite limited due to factors such as 
cost and safety.  The use of driving simulators is an alternative with superior validity to simple 
laboratory measures and obviate any safety concerns inherent to an impaired person operating a 
vehicle in normal traffic.  An increase in vehicle standard deviation of lane position (i.e., lateral 
movement/weaving) caused by a drug is associated with increased crash risk, and this is the 
primary outcome measure reported in both on-the-road and simulated driving studies.  
 
Alprazolam is a benzodiazepine often prescribed off-label for sleep.  Effects are mediated by 
increased GABAergic activity and include sedation and psychomotor impairment; and with a 
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half-life of 11hr, it is possible that these effects would persist long after falling asleep.  Like 
zolpidem, this may result in increased crash risk the morning after its use.  That hypothesis is 
supported by epidemiological studies indicating that prescription of benzodiazepines as a class 
(and alprazolam specifically) is associated with a higher risk of traffic accidents.  The time course 
of alprazolam-induced impairment has not been fully characterized.  
 
There are many factors which may influence individual drug response.  Sex differences in drug 
pharmacokinetics and pharmacodynamics have been underappreciated and understudied, in part 
due to grossly disproportionate clinical trial participation by men and women.  Women are 
prescribed drugs more often and have more adverse drug reactions than men, but for drugs 
approved before 1993 (e.g., alprazolam), women were prohibited from participating in the clinical 
trials determining their safety and efficacy.  Many drugs exhibit sex-specific effects.  The 
increased crash risk associated with zolpidem use was almost exclusively seen in women due to 
their reduced clearance of the drug compared to men.  Alprazolam is a lipophilic drug that may 
display a similar pattern of sex-specific driving impairment.  Few studies assessing drug-induced 
driving impairment have included adequate numbers of both men and women to perform a sex 
difference analysis (and no such study has been conducted for alprazolam)—representing a 
significant gap in the literature.   
 
Pharmacodynamic evaluation of the time course of alprazolam effects, specifically on driving 
ability, the day after bedtime administration is needed, as is an assessment of possible sex-
differences in those effects.  
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Table 1.1 United States traffic fatality statistics, 2007-2016 
 
Total Deaths a 
 
Deaths per 100,000 
population b 
Deaths per 100 million 
vehicle miles driven a 
2007 41,259 13.70 1.36 
2008 37,423 12.32 1.26 
2009 33,883 11.05 1.15 
2010 32,999 10.67 1.11 
2011 32,479 10.42 1.1 
2012 33,782 10.76 1.14 
2013 32,893 10.40 1.05 
2014 32,744 10.28 1.08 
2015 35,485 11.06 1.15 
2016 37,461 11.59 1.18 
a Deaths and vehicle miles driven data from NHTSA (NHTSA 2017) 
b Population statistics from US Census Data (USCB 2018) 
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Table 1.2 Alcohol test statistics for fatally injured drivers, 2007-2016 
 
Total  Tested for Alcohol a  Positive Test Result 
(#)  (#) (%)  (#) (% of total) (% of those tested) 
2007 26,570   19,434  73.14   8,127  30.59 41.82 
2008 24,254   18,415  75.93   7,762  32.00 42.15 
2009 21,835   16,761  76.76   7,044  32.26 42.03 
2010 21,072   16,405  77.85   6,657  31.59 40.58 
2011 20,815   15,846  76.13   6,362  30.56 40.15 
2012 21,490   16,097  74.90   6,524  30.36 40.53 
2013 20,943   15,661  74.78   6,264  29.91 40.00 
2014 20,788   15,352  73.85   6,048  29.09 39.40 
2015 22,348   16,469  73.69   6,275  28.08 38.10 
2016 23,560   14,453  61.35   5,473  23.23 37.87 
a Numbers reflect only those drivers tested who have a known result recorded in the FARS 
database. Approximately 2 – 4% of drivers listed as receiving an alcohol test have unknown 
results. 
 
 37 
 
Table 1.3 Alcohol test statistics for drivers involved in fatal accidents, 2007-2016 
 
Total  Tested for Alcohol a  Positive Test Result 
(#)  (#) (%)  (#) (% of total) (% of those tested) 
2007 56,019  27,048 48.28  10,535 18.81 38.95 
2008 50,416  26,046 51.66  10,000  19.83 38.39 
2009 45,291  23,906 52.78   9,114  20.12 38.12 
2010 44,599  24,291 54.47   8,779 19.68 36.14 
2011 43,840  23,303 53.15   8,291 18.91 35.58 
2012 45,664  23,631 51.75   8,496 18.61 35.95 
2013 44,803  22,597 50.44   8,127 18.14 35.96 
2014 44,671  22,053 49.37   7,827 17.52 35.49 
2015 49,162  23,855 48.52   8,125 16.53 34.06 
2016 51,914  20,945 40.35   6,997 13.48 33.41 
a Numbers reflect only those drivers tested who have a known result recorded in the FARS 
database. Approximately 2 – 4% of drivers listed as receiving an alcohol test have unknown 
results. 
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Table 1.4 Drug test statistics for fatally injured drivers, 2007-2016 
 
Total  Tested for Drugs a  Positive Drug Test Result 
(#)  (#) (%)  (#) (% of total) (% of those tested) 
2007 26,570  14,921 56.16  4,198 15.80 28.13 
2008 24,254  14,394 59.35  4,258 17.56 29.58 
2009 21,835  12,371 56.66  4,323 19.80 34.94 
2010 21,072  13,033 61.85  4,551 21.60 34.92 
2011 20,815  12,608 60.57  4,696 22.56 37.25 
2012 21,490  13,049 60.72  5,074 23.61 38.88 
2013 20,943  12,650 60.40  5,042 24.07 39.86 
2014 20,788  12,665 60.92  5,171 24.87 40.83 
2015 22,348  13,777 61.65  5,977 26.75 43.38 
2016 23,560  12,296 52.19  5,365 22.77 43.63 
a Numbers reflect only those drivers tested who have a known result recorded in the FARS 
database. Approximately 3 – 5% of drivers listed as receiving a drug test have unknown 
results. 
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Table 1.5 Drug test statistics for drivers involved in fatal accidents, 2007-2016 
 
Total  Tested for Drugs a  Positive Drug Test Result 
(#)  (#) (%)  (#) (% of total) (% of those tested) 
2007 56,019  18,645 33.28  5,262   9.39 28.22 
2008 50,416  18,335 36.37  5,422 10.75 29.57 
2009 45,291  16,176 35.72  5,500 12.14 34.00 
2010 44,599  17,445 39.12  5,946 13.33 34.08 
2011 43,840  16,970 38.71  6,096 13.91 35.92 
2012 45,664  17,459 38.23  6,572 14.39 37.64 
2013 44,803  16,761 37.41  6,540 14.60 39.02 
2014 44,671  16,806 37.62  6,640 14.86 39.51 
2015 49,162  18,530 37.69  7,738 15.74 41.76 
2016 51,914  16,215 31.23  6,982 13.44 43.06 
a Numbers reflect only those drivers tested who have a known result recorded in the FARS 
database. Approximately 3 – 5% of drivers listed as receiving a drug test have unknown 
results.  
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Table 1.6 Most commonly detected prescription drugs in fatally injured drivers, 2007-2016 
 
Drug (number of drivers testing positive) 
 
1st 2nd 3rd 4th 5th 
2007 AMP (253) BZO (163) HC (147) METH (118) MTD (105) 
2008 AMP (226) HC (193) BZO (187) ALP (138) METH (109) 
2009 AMP (215) HC (213) BZO (207) ALP (131) OXY (121) 
2010 HC (241) AMP (231) ALP (198) OXY (153) DIA (124) 
2011 HC (284) AMP (248) ALP (229) OXY (152) BZO (147) 
2012 AMP (318) HC (280) ALP (188) BZO (186) OXY (152) 
2013 AMP (390) HC (269) ALP (200) BZO (178) OXY (145) 
2014 AMP (371) HC (215) ALP (212) METH (182) BZO (173) 
2015 AMP (488) HC (254) ALP (237) BZO (227) METH (222) 
2016 AMP (449) ALP (239) METH (207) HC (180) OXY (151) 
ALP = alprazolam, AMP = amphetamine, BZO = benzodiazepine (unspecified type), DIA = 
diazepam, HC = hydrocodone, METH = methamphetamine, MTD = methadone, OXY = oxycodone 
 
Methamphetamine is prescribed under the trade-name Desoxyn, but may also cross-react with 
amphetamine (prescribed under the trade name Adderall) depending on the sensitivity of the drug 
assay utilized for testing.   
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Table 1.7 Standard deviation of lane position (SDLP) after placebo and alcohol in 16 studies  
  SDLP (cm) at BrAC at beginning of driving task D SDLP 
 
Study & task  
.00 
 
.02 
 
.03 
 
.04 
 
.05 
 
.06 
 
.08 
 
.10 
 
.05 – 
0.00 
.08 – 
0.00 
On-the-road driving task (100km, highway)  
  Kuypers et al. (2006) 20.6   23.5       
  Louwerens et al. (1987) a         2.4 4.1 
  Ramaekers et al. (2000)  22.3   24.4       
  Schumacher (2011) 18.3    20.7    2.4  
  Schumacher et al. (2014)  18.0    20.7    2.7  
  Van der Sluizen et al. (2016) 17.0   19.4       
  Vermeeren et al. (2002a)  20.0   22.3       
  Vermeeren et al. (2002b)  17.7   19.4       
  Verster and Roth (2012) a         1.3  
  Average         2.0 4.1 
Driving simulator task     
  Berthelon and Gineyt (2014)           
      Highway route (15min) 26.4  25.9  28.4  31.9  2.0 5.5 
      Following route (10min) 18.4  19.2  19.7  23.3  1.3 4.9 
  Hartman et al. (2016) 31.4 32.3   33.6  34.8 35.7 2.2 3.4 
  Lenne et al. (2003)  31.3     40.5     
  Lenne et al. (2010) 36 41   41    5  
  Kenntner-Mabiala et al. (2015)           
      Rural nighttime (24km) 17    19  20  2 3 
      Car following (2km) 20    23  25  3 5 
      Winding road (5km) 21    21  22  0 1 
  Mets et al. (2011) 28.0    29.7  33.8 36.3 1.7 5.8 
  Veldstra et al. (2012) 15.8  17.7  17.9  19.9  2.1 4.1 
  Average         2.1 4.1 
a Indicates that raw SDLP data not reported; thus, only change from placebo scores are listed.  
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Figure 1.1 Chemical structure of alprazolam, diazepam, and zolpidem.  Alprazolam (left) and 
diazepam (middle) are both comprised of the benzodiazepine core: a benzene ring (six-membered 
ring comprised of carbon atoms with one hydrogen atom attached to each) fused to a diazepine 
ring (a seven-membered heterocyclic compound with two nitrogen atoms) as well as an additional 
aryl ring attached at the 5’ position of the diazepine ring.  Alprazolam has an additional triazole 
ring (highlighted in red).  Zolpidem (right) contains structures similar to the benzodiazepines: a 
imidazopyridine (six-membered ring with five carbon and one nitrogen atom fused to a five-
membered ring with two nitrogen atoms) and an aryl ring.  
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CHAPTER II. HYPOTHESIS 
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Bedtime administration of alprazolam will dose-dependently cause psychomotor impairment that 
is detectable after a night’s sleep.  
 a) Participants will be unaware of the extent of their own impairment.  
b) Impairment will be of greater magnitude and longer duration in females compared to 
males.   
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CHAPTER III.  MATERIALS & METHODS 
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Volunteers 
Study volunteers were 14 (6 male) non-nicotine-product-using adults (age 18 to 50) who 
possessed a valid driver’s license.  Volunteers were carefully screened to exclude those with a 
seizure disorder, acute narrow-angle glaucoma (as it is contraindicated for alprazolam), lifetime 
history of benzodiazepine physical dependence, current physical dependence on any substance 
except caffeine, or clinically significant ongoing medical problems (e.g., diabetes, hypertension, 
etc.).  All volunteers were determined to be in good physical and psychiatric health by medical 
history and physical examination, an ECG and laboratory tests, and exam by a psychiatrist.  A 
complete list of the inclusion/exclusion criteria for the study can be found in Appendix 2.  
Screening assessments included the NEO Personality Inventory (Costa and McCrae 2008), 
Symptom Checklist-90 (Derogatis et al. 1976), Beck Depression Inventory (Beck et al. 1961), 
Columbia Suicide Severity Scale (Posner et al. 2011), and the Wide Range Achievement Reading 
Test (Jastak 1984).  Volunteers provided urine and breath samples to be tested for illicit drugs 
(American Screening, LLC; Shreveport, LA), alcohol, carbon monoxide, and pregnancy during 
each screening visit.  The 11-panel drug test card detected the following substances: 
benzodiazepines, barbiturates, cocaine, tetrahydrocannabinol (THC), methamphetamine, 
morphine-derivative opiates (e.g. heroin), methadone, oxycodone, phencyclidine (PCP), 
amphetamines, and buprenorphine.  Volunteers were recruited through local print and online 
advertisements and by word of mouth, and they were paid for their participation.  The University 
of Kentucky Institutional Review Board approved this study, and volunteers gave their written 
informed consent prior to the conduct of study procedures.  This study was conducted in 
accordance with the Helsinki guidelines for ethical human research.  
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Study Design and Setting 
This study employed a randomized, placebo-controlled, mixed-factorial design (with sex as the 
between-subject factor).  It was conducted at the University of Kentucky Center on Drug and 
Alcohol Research and the Center for Clinical and Translational Sciences inpatient unit located in 
the University of Kentucky Hospital.  After screening procedures were finished, volunteers 
completed a practice session to familiarize them with the session tasks.  No drugs were 
administered during this session.  Volunteers then completed a total of six overnight experimental 
sessions scheduled at least two days apart to ensure adequate wash-out of drugs between sessions.  
Breath and urine samples were collected twice during each session—once upon arrival in the 
afternoon and again in the morning to ensure that no alcohol or drugs (other than those 
administered as part of the study) were consumed while the volunteer was on the research unit for 
the night.  Women were tested for pregnancy at the same interval.  No study procedures (i.e., drug 
administration) were conducted if a volunteer tested positive for illicit drugs, alcohol, or 
pregnancy at the beginning of a session.   
 
Study Drugs 
Each session included two drug administrations: one at bedtime (~11:30 PM) and one the 
following morning (~8:30 AM), though only one dose per session was active—the other dose was 
placebo.  Six dose conditions were evaluated during the study (bedtime dose/morning dose): 
alprazolam 0.5mg/placebo, alprazolam 1.0mg/placebo, alprazolam 2.0mg/placebo, zolpidem 
10mg/placebo, placebo/placebo, and placebo/alprazolam 1.0mg.  All doses were placed into size 
00 capsules and loose-filled with lactose powder.  Placebo doses consisted of identically 
appearing capsules loose-filled with lactose powder.  All study medication was prepared in the 
University of Kentucky Investigational Drug Service Pharmacy by a licensed pharmacist.  Doses 
administered on the inpatient unit were stored at the pharmacy until dosing.  Drugs administered 
in the morning at the Center on Drug and Alcohol Research Building were stored in a locked 
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drawer in a limited-access drug storage room.  All drugs, capsules, and filler were obtained from 
commercial sources through the University of Kentucky hospital formulary.  
 
Dose Selection Rationale 
Previous laboratory studies have safely administered alprazolam doses of 2mg to non-patient 
populations (Smith and Kroboth 1987, Norman et al. 1990).  Alprazolam doses used clinically 
range from .75mg to 4mg daily, given in divided doses.  While controlled data for alprazolam 
doses used off-label for sleep are lacking, internet drug abuse-oriented forums suggest doses of 
0.125 to 2mg are used (Bluelight 2012).  Commonly prescribed doses of 0.5, 1 & 2mg alprazolam 
were ultimately selected to 1) ensure volunteer safety and 2) maximize public health relevance. 
The daytime positive control (alprazolam 1mg) has been shown to cause acute impairment in 
psychomotor tasks (including on-the-road driving).  Zolpidem 10mg was also included because it 
is the dose at which the FDA considers significant impairment to occur in women the morning 
after bedtime use; thus, it serves as a regulatory benchmark and clinical control condition.  
Although controlled-release (CR) zolpidem formulations result in the highest blood 
concentrations and subsequent impairment, the immediate-release formulation is of greater public 
health relevance as zolpidem CR is prescribed at approximately 1/10th the rate of zolpidem IR.  
The inclusion of zolpidem allows for exploration of relative impairment caused by an FDA-
approved sleeping medication to that of a medication often used off-label for sleep. 
 
Experimental Sessions 
Volunteers were initially trained on all study tasks during a practice session.  For the six 
experimental sessions, volunteers arrived at the laboratory in the afternoon and were evaluated for 
continued qualification (i.e., inclusion criteria all met and no exclusion criteria met).  This 
evaluation included a history and physical exam update conducted by a study physician.   
Baseline (pre-drug administration) assessments were completed, and volunteers were escorted to 
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the Center for Clinical and Translational Science inpatient unit.  Volunteers were allowed to eat 
until three hours prior to drug administration, after which food was restricted.  Water was allowed 
at all times.  Nursing staff supervised the administration of the single capsule at 11:30 PM, and 
volunteers were instructed to sleep immediately following drug administration.  A research 
assistant woke the volunteers 7.5hr after drug administration and escorted them to the driving 
simulator laboratory, where the remainder of the session took place.  A light breakfast (including 
a single cup of coffee or caffeinated tea if desired) was consumed and the morning baseline 
assessments were conducted.  The second drug administration occurred nine hours after the first 
(at approximately 8:30 AM).  Volunteers completed driving simulations, responded to computer 
questionnaires, and performed other tasks under the supervision of a trained research assistant.  
Data were collected for 5hr after the morning drug administration.  Table 2.1 details the timing of 
all pharmacodynamic measures.  
 
Outcome Measures 
Driving Simulator Task   
The Driving Simulator:  A National Advanced Driving Simulator MiniSimTM 
computerized driving simulator was used to conduct driving tasks.  Operation of the simulator 
required the use of a steering wheel, accelerator and brake pedals.  Computer-generated graphics 
were displayed on three 20in LCD monitors, one fixed 15in directly in front of the driver, and 
two at 150-degree angles providing peripheral coverage.  An additional monitor displayed the 
instruments panel (speedometer, gear indicator, etc.).  Audio output included engine noise, wind, 
tire squeal, Doppler Effects of passing vehicles, and impact sounds in cases of collision.  Also in 
the event of a collision, a tactile transducer created low-frequency vibrations to shake the 
MiniSimTM apparatus and driver.  The simulation lasted approximately 10min. The driving 
scenario began as a rural two-lane highway in which the volunteer accelerated up to the speed 
limit.  The highway continues for approximately two miles before on-screen and spoken 
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instructions indicate that the volunteer should take the next exit.  After the off-ramp, the 
simulation becomes a rural road followed by suburbs and finally a city.  Several incursion events 
are placed throughout the simulation: a car braking suddenly on the highway, a pedestrian 
walking directly in front of the volunteer car, a car pulling into the road in front of the volunteer 
car, and a poorly parked car blocking part of the volunteer’s lane which they must navigate 
around.  Outcome measures include standard deviation of lane position (SDLP; a marker of 
swerving and the primary outcome measure), standard deviation of speed, and tactical measures 
(e.g., deceleration in response to an obstacle).   
 
The primary outcome measure, SDLP, was calculated in three steps: 
1.  Data were edited to include only valid data points and data points of interest.  Two 
measures of SDLP were initially calculated: one from the entire drive and one from a short 
straight section of highway.  On-the-road driving tests are conducted in a highway setting; thus, 
this second measure may be more easily compared to SDLP outcomes in those studies.  Because 
the ‘whole drive’ SDLP includes many more data points than the ‘highway’ SDLP, it would be 
expected that the whole drive SDLP would be smaller.  Any occasion in which the volunteer 
makes a full lane change was removed from the data.  See Figure 2.1 for driving data editing 
details.   
 
2.  The lateral position [X] for each valid data point was determined and the mean (µ) 
calculated.  A single mean lateral position (MLP) for the simulation section of interest was 
generated from the following formula: 
MLP [X] = µ  
 
 51 
3.  The standard deviation of the MLP across all valid samples [X] was calculated using 
the following formula:   
 !"#$ = 	 '#$	[(*-µ)-]   
 
In order to promote conscientious driving, volunteers were paid a performance-based bonus of $5 
for each drive if they followed the rules of the road and instructions from study staff. 
 
 
Subjective Assessments Related to the Driving Simulator Task 
Driving Visual Analog Scales (VAS):  Immediately after each driving simulation, 
volunteers rated the following items: ‘I drove the previous simulation well, I drove within the 
posted speed limits, and I feel safe to drive on the road’ on a 100-point line with the terms 
‘Disagree Completely’ on the far left (at 0) and ‘Agree Completely’ on the far right (at 100). 
 
Simulator Sickness Questionnaire (SSQ) (Kennedy et al. 1993):  The SSQ is a validated 
tool for quantifying adverse reactions to simulated driving environments.  It uses a four-point 
scale (from none [scored 0] to severe [scored 3]) to rate the following 27 symptoms which are 
commonly experienced by users of virtual reality systems: general discomfort, fatigue, headache, 
eyestrain, difficulty focusing, increased salivation, sweating, nausea, difficulty concentrating, 
blurred vision, fullness of head, dizzy, vertigo, stomach awareness, and burping.  Scores for three 
subscales (nausea, oculomotor problems, disorientation) were calculated.  
 
Other Psychomotor Assessments 
The Circular Lights Task:  Also known as the Wayne Saccadic FixatorTM task, this task 
consists of a square panel with 33 red light switches which the volunteer presses to extinguish.  
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Lights appear randomly on the panel, and volunteers were instructed to use their pointer finger to 
extinguish as many lights as possible in 1min.  Performance on this task is related to reaction 
time, hand-eye coordination, and peripheral awareness.  
 
The Digit Symbol Substitution Task (DSST) (McLeod et al. 1982):  The DDST is a timed 
task requiring volunteers to replicate a pattern presented on a computer screen using a numeric 
keypad, and performance is related to attention, visual scanning and memory.  Volunteers were 
instructed to complete as many correct patterns as possible in 90sec.  Additionally, volunteers 
were asked to rate ‘How well do you think you will perform on the DSST compared to normal?’ 
prior to starting and ‘How well do you think you did perform the DSST compared to normal?’ 
after finishing.  Ratings were completed on a 100mm VAS anchored at -50 (much worse), 0 
(normal), and 50 (much better).  
 
The SafeDrive Application (Miceli et al. 2015):  This phone and tablet application 
assesses auditory and visual reflexes and is currently being used by the Italian police force to 
assess impairment in drivers who test negative for breath alcohol.  It consists of four short tests 
(simple visual, complex visual, simple auditory, complex auditory) and provides results in deciles 
compared to the general population.  Outcomes analyzed were test completion time and whether 
each test was passed or failed.  
 
 
Assessments of Subjective Drug Effect 
Drug Visual Analog Scales (VAS):  Volunteers rated the following items: ‘Do You 
Feel…Any Drug Effect, Good Effects, Bad Effects, High?’ and ‘Does the Drug Make You 
Feel…Nauseated, Confused, Dizzy, Tired, Irritable?’ on a 100-point line anchored with the terms 
‘none at all’ at the far left (at 0) and ‘extremely’ at the far right (at 100).   
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The Adjective Checklist:  Volunteers rated (on a scale from 0 [not at all] to 4 [extremely]) 
the following signs/symptoms of alprazolam and zolpidem: dizzy, upset stomach, irritable, 
relaxed, drunken, slurred speech, difficulty concentrating, heavy/sluggish, dry mouth, 
lightheadedness, sleepy, weak, nervous, uncoordinated, and confused.  
 
The Observer Adjective Checklist:  Trained research assistants rated (on a scale from 0 
[not at all] to 4 [extremely]) the visually observable signs and symptoms from the Adjective 
Checklist (i.e., nervous, drunken, irritable, slurred speech, relaxed, sleepy, clumsy, sluggish, 
confused, and dazed/spaced-out).  
 
Sleep Measures 
Sleep VAS:  Approximately 1hr after waking each session, volunteer perception of sleep 
quality was assessed with the following items: ‘I slept well last night’, ‘I fell asleep easily last 
night’, ‘I feel clear-headed this morning’, ‘I woke up often last night’, I am satisfied with my 
sleep last night.’  Responses were recorded on a 100-point line anchored with the terms ‘not at 
all’ at the far left (at 0) and ‘extremely’ at the far right (at 100).  These questions have been used 
previously to detect drug effects on subjective sleep quality (Haney et al. 2004).  
 
Fitbit:  A wrist monitor was worn from a volunteer’s arrival at the inpatient unit until 
waking the next morning to track sleep duration and quality. 
 
 
Physiological Measures   
In-session measures:  Heart rate, blood pressure, and respiration rate were collected every 
30 minutes during the experimental session.  Heart rate and blood pressure were collected using a 
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Dinamap Non-Invasive Patient Monitor (GE Medical Systems, Tampa, FL, USA) and respiration 
rate was assessed visually over 60 seconds by a trained research assistant or nurse.   
 
Body fat percentage:  A dual-energy x-ray absorptiometry (DXA) scan was performed on 
one visit to determine total body fat percentage.  
 
 
Statistical Analyses 
Standard deviation of lane position (SDLP) was the primary outcome measure.  Each drive 
yielded two SDLP outcomes—one calculated using mean lateral position from the entire drive 
and one calculated using mean lateral position during a short (~1-mile) section of uneventful 
highway within the drive.  In order to determine which of these two outcomes was more 
appropriate to use as the primary outcome measure, the mean, range, and variance in both were 
calculated for each volunteer’s pre-drug baseline drives in all six sessions.  On-the-road driving 
studies have demonstrated that SDLP is a stable measure within subject; thus, the SDLP outcome 
measure with the least within-subject variability across six sessions was selected as the primary 
outcome measure.  
 
Two analytic approaches were utilized for hypothesis testing—symmetry analysis (Laska et al. 
2012) and mixed models analysis.  The primary outcome measure was analyzed using both 
methods.  All other outcomes were analyzed using a mixed-models approach only.  Analyses 
were conducted using SAS 9.3, and statistical significance was set at p < .05.   
 
Symmetry analyses 
Because analyses of mean (group-level) changes may be insensitive to clinically meaningful 
impairment (due to large inter-person variability in pharmacodynamic effects—see introduction), 
 55 
the FDA recommends symmetry analysis to evaluate drug effects on the ability to operate a motor 
vehicle (FDA 2015).  Symmetry in SDLP implies that the probability of improvement after an 
active dose (relative to the negative control—i.e., placebo) is the same as the probability of 
impairment.  An increase in SDLP of 2.4cm relative to placebo reflects the impairment seen at a 
BAC of 0.05% (Leufkens et al. 2009, Verster et al. 2014); thus, 2.4cm was used as the initial 
threshold for impairment.  For each individual volunteer, the difference in SDLP (active – 
placebo) was calculated at each post-drug administration timepoint.  The distribution of the 
difference in SDLP at each active dose and timepoint was then analyzed with a McNemar test to 
detect asymmetry.  If the distribution of SDLP differences after active dosing show a random 
pattern (i.e., the number of volunteers with changes in SDLP above +2.4cm and below -2.4cm are 
not different), then the active dose has no impairing effect.  If significantly more volunteers 
exhibit changes in SDLP above +2.4cm than below -2.4cm after an active dose compared to 
placebo, that dose increases the risk of impaired driving performance.  To further characterize the 
magnitude of driving impairment risk, additional McNemar tests were used to determine 
asymmetry in distributions around thresholds of 4.1cm and 5.3cm (indicative of impairment 
equivalent to that at 0.08% and 0.10% BAC, respectively). 
 
Mixed model analyses 
All measures were first analyzed as raw time course data using a three-factor (Sex x Dose x 
Time) model with sex as the between-subject factor.  Emax scores (either peak or trough as 
appropriate) were then calculated for each individual subject and dose condition and analyzed in a 
two-factor (Sex x Dose) mixed model.  Both time course and Emax mixed-models analyses 
incorporated the following variables as covariates: age, body fat percentage, and subjective sleep 
quality reported (on a 100-point visual analog scale) approximately 1hr after waking each session.  
Tukey’s post-hoc tests were performed to examine time course of drug effects, active dose effects 
compared to the placebo and zolpidem doses, and differences between males and females.  
56 
-.5 0 .5 1 1.5 2 3 4 5
Drug Visual Analog Scales 
Driving Simulation
Driving Visual Analog Scales 
Simulator Sickness Questionnaire 
Safe Drive Application Adjective 
Checklist
Observer Adjectives Checklist 
Vitals
Circular Lights Task
Digit Symbol Substitution Task
D
ay
tim
e 
D
ru
g 
A
dm
in
ist
ra
tio
n
2.5 3.5 4.5
Table 2.1 Schedule of data collection during experimental sessions
Time (hours, relative to daytime drug) 
Time (hours, relative to bedtime drug) 
-8.5
Be
dt
im
e 
D
ru
g 
A
dm
in
ist
ra
tio
n
8 8.5 9 10 10.5 11 11.5 12 12.5 13 13.5 140
.25
8.75
-.75
7.75
57 
Figure 2.1 Editing raw lane position data from a driving simulation.  The blue line shows the lateral 
position of the car throughout the drive.  If the car is perfectly centered in the lane, the line is at 0.  
Deviation toward the left is represented by a negative number, and deviation toward the right of the lane is 
represented by a positive number.  The yellow and red circles indicate when the car is departed from the 
lane (i.e., when more than 50% of the car crosses over the lane lines.  A) A lane change maneuver: these 
data are removed from calculation of SDLP.  B) A lane departure: these data are included in calculation of 
SDLP.  
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CHAPTER IV.  RESULTS 
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Recruitment Statistics and Baseline Subject Characteristics 
Figure 3.1 displays the flow of volunteer recruitment and participation.  Demographic 
characteristics and results of screening assessments are listed in Table 3.1.  The only 
characteristic or screening assessment results that were significantly different between male and 
female volunteers were height and body fat percentage.  Of the eight female volunteers, three 
used hormonal contraception (two intra-uterine devices and one oral contraceptive) and two had a 
tubal ligation.  
 
 
Part I. Validating the Primary Outcome Measure  
Figure 3.2 displays the SDLP from the baseline drive of all six study sessions for each volunteer, 
and within-subject descriptive statistics (mean, range, variance) are listed in Table 3.2.  Two 
separate measures of SDLP were calculated for each drive: the first is from the entire simulation 
and the second is from a stretch of straight highway (more akin to the conditions used in the on-
the-road driving studies).  As can be seen in both Figure 3.2 and Table 3.2, baseline SDLP 
variability was greater for the highway section of the drive than the whole drive; for this reason, 
the more stable whole drive SDLP measurement was used for analyses below.   
 
SDLP was also generally greater in females than males.  A visual inspection of the data suggested 
that the subjects with the largest SDLP variability in their baseline drives were the oldest in the 
sample.  Pearson correlations (age x baseline drive SDLP variance) indicated that there was a 
positive (though non-statistically significant) relationship between volunteer age and baseline 
drive SDLP variance (see Figure 3.3).  
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Part II. Hypothesis Testing and Study Results 
Driving Simulator Task 
Failure to complete the driving task 
One female volunteer was unable to complete the driving task 1hr after the daytime alprazolam 
1mg dose was administered.  Approximately four minutes after the task began, the volunteer 
nodded off and subsequently drove the car off the side of a highway off-ramp situated on a steep 
hill.  At that point, the simulation was automatically terminated by the computer because the car 
moved outside the programmed area.  Her data were included in the statistical analyses.  She was 
able to complete the subjective and other psychomotor task battery.   
Standard deviation of lane position (SDLP) 
Symmetry analysis:  SDLP changes from placebo for each active dose for the first four 
drives are displayed in Figure 3.4.  Impairment equivalent to that seen with a .10% BAC was 
detected 8.5hr after the bedtime zolpidem 10mg condition (McNemar Statistic = 8, p = .005); this 
effect was strongest in females and dissipated by 9.5hr after drug administration.  The bedtime 
alprazolam 2mg dose was equally impairing at the first morning timepoint in both sexes 
(McNemar Statistic = 12, p = .001).  Significant impairment equivalent to 0.05% BAC was still 
detected at the group (n = 14) level at 12.5 and 13.5hr after bedtime alprazolam 2mg 
administration (McNemar Statistic = 4.45 – 5.00, p < .05).  The daytime alprazolam 1mg dose 
was robustly impairing in both males and females starting 1.5hr after drug administration (see 
Figure 3.4).  Significant impairment equivalent to 0.10% and 0.05% BAC was still detected at the 
group (n = 14) level at 3.5 and 4.5hr after daytime alprazolam 1mg administration, respectively 
(McNemar Statistic = 4.45 – 8, p < .05).   
Because body fat percentage was predicted to be a significant contributing factor to time 
course of alprazolam impairment effects, Pearson and Spearman Correlations were conducted to 
 61 
explore potential associations between body fat percentage and SDLP change from placebo at 
doses and timepoints for which significant impairment was found using symmetry analyses.  
Correlations were all non-significant (p > .05), and no clear association was observed.  
Time course analysis:  As seen in the top row of Figure 3.5, dose effects on SDLP were 
evident for the daytime alprazolam 1mg dose and bedtime alprazolam 2mg doses in both males 
and females.  For the active bedtime doses, the largest effects were observed at the first morning 
timepoint (~8:30 AM), but after the daytime alprazolam 1mg dose, the largest effects were 
observed approximately 1hr after dosing (~9:30 AM).  Visual inspection of the data indicates that 
SDLP remained elevated compared to placebo for longer in females (timepoint 1.5hr - 3.5hr) than 
males (timepoint 1.5hr), though this effect was non-significant (Tukey’s post hoc test, p > .05).  
Likewise, an area-under-the-curve analysis by sex was non-significant, p > .05.  
Emax analysis:  The largest SDLP was observed after the daytime alprazolam 1mg dose 
and the bedtime alprazolam 2mg dose (See Table 3.3 for means and SEMs).  Although peak 
SDLP did not vary as a function of sex, the difference was largest after the bedtime zolpidem 
10mg dose (see top left of Figure 3.6). 
Secondary weaving variables 
Time course analysis: Figure 3.5 (middle row) displays the time course for percent of the 
drive departed from lane.  For active bedtime doses, more time departed from the lane was seen at 
the earliest timepoints.  For the daytime alprazolam 1mg condition, there was an increase 1.5hr 
after drug administration.  This increase persisted in females, but not males, for 3hr.  The total 
number of lane departures made during a drive followed a similar pattern of results, with a 
significant effect of Dose [F(5,60) = 3.25, p = .012] and a Dose x Time interaction [F(30,360) = 
2.02, p = .002].  
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Emax analysis: When analyzed as a peak score, there was a significant main effect of 
Dose for both number of lane departures [F(5,58) = 8.44, p < .0001] and percent of time departed 
from the lane [F(5,58) = 6.65, p < .0001].  Means (SEMs) are listed in Table 3.3. Although peak 
percent time departed from lane did not vary as a function of sex, the difference was largest after 
the bedtime zolpidem 10mg dose (see top right of Figure 3.6), with females spending more time 
departed from their lane than males.  
Speed-related variables 
Time course analysis:  Standard deviation of speed (SDS) was insensitive to dose effects 
(see the bottom of Figure 3.5); but when collapsing across dose conditions, males (M ± SEM:
15.67 ± 0.03mph) displayed significantly greater variability in speed than females (M ± SEM:
14.85 ± 0.05mph).   There were no significant main effects or interactions for percent time
driving 5mph or more over the speed limit, p > .05. 
Emax analysis:  When analyzed as a peak score, there were no significant effects or 
interactions for SDS or percent time driving 5mph or more over the speed limit, p > .05.  As seen 
in the lower right of Figure 3.6, the trough mean speed (i.e., the mean speed of the drive which 
the volunteer completed the slowest) was typically lower in females than males.  
Collisions 
Collisions were rare.  During the course of 168 post-drug administration drives, only 20 
collisions occurred.  Three collisions occurred during baseline drives; but as these are not 
attributable to drug effect, they were excluded from further description.  Females crashed more 
frequently than males (15 vs. 5) and were most likely to crash after the daytime alprazolam 1mg 
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dose (7 collisions).  Four of those seven collisions occurred 4.5hr after dosing—during the last 
drive of the session.  For males, one collision occurred after each dose condition except the 
bedtime alprazolam 2mg dose.  
Incursion events 
Time course analysis:  Three-factor (Sex x Dose x Time) revealed no significant effects 
or interactions for distance between the incursion object and the volunteer car at the time of 
braking, minimum time-to-collision with the incursion object, or reaction time to press the brake 
in response to the incursion object, p > .05. 
Emax analysis:  There were no significant main effects or interactions for peak reaction 
time to press the brake in response to the incursion object, trough distance between the incursion 
object and the volunteer car at the time of braking, or trough minimum time-to-collision with the 
incursion object, p > .05. 
Subjective Assessments Related to the Driving Simulator Task 
Driving Visual Analog Scales (VAS) 
Time course analysis:  For males and females, driving difficulty was rated high after the 
daytime alprazolam 1mg condition; and for males at the first morning drive after the bedtime 
alprazolam 1mg (23.33± 15.91) and 2mg (43.33 ± 13.87) conditions.  After administration of the
daytime alprazolam 1mg dose, males reported driving difficulty dropped to 4.33  ± 4.33 (i.e., not
at all difficult) by the final drive 4.5hr after drug administration, but females reported driving 
difficulty at 24.38 ± 11.77 (out of 100) at that same dose and timepoint (see Figure 3.7).
Volunteers rated their ability to drive safely in a real car lowest after the daytime alprazolam 1mg 
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condition.  In males, there was also a decrease in perceived safety after the bedtime alprazolam 
1mg and 2mg conditions (see Figure 3.7).  Obeying speed limits was rated lowest after the 
daytime alprazolam 1mg condition for both males and females (see Figure 3.7).  An AUC 
analysis by sex was non-significant. 
Emax analysis:  There was a main effect of Dose for peak score for the Driving VAS 
item “Driving was difficult,” and for trough scores for the items “I performed the previous 
simulation well,” and “I could drive safely in a real car right now.”  Means (SEMs) collapsed 
across sex are listed in Table 3.3.  Although Driving VAS Emax scores did not vary as a function 
of sex, p > .05, females reported that driving was more difficult and that they felt less safe to 
drive in a real car than males after the bedtime zolpidem 10mg dose (see Figure 3.8).  
Simulator Sickness Questionnaire (SSQ) 
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model analyses revealed 
significant effects of Sex, Dose, and Time for the three subscale scores (see Figure 3.9).  In 
general, females reported more symptoms at each dose condition, and symptoms remained 
elevated longer than for males.  The highest SSQ scores were reported after the daytime 
alprazolam 1mg condition.  
Emax analysis:  Peak subscale scores are displayed as a function of dose and sex in 
Figure 3.10.  Peak scores were higher for females than males after all active doses, with the 
largest difference observed after the bedtime zolpidem 10mg dose.  These differences were non-
significant in the two-factor model, and means (SEMs) collapsed across sex for scores with a 
significant effect of Dose (oculomotor, disorientation) are listed in Table 3.3.  Scores were dose-
related.  
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Other Psychomotor Assessments 
The Circular Lights Task 
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model data are displayed 
in the top of Figure 3.11.  In general, the fewest lights were extinguished after administration of 
the daytime alprazolam 1mg dose and the bedtime alprazolam 2mg dose.  While sex was not a 
significant factor, females typically extinguished fewer lights than males (M ± SE collapsed
across dose: [males 85.42 ± 0.46, females 80.50 ± 0.41]), particularly after the daytime
alprazolam 1mg dose. 
Emax analysis:  Trough means (SEMs) for each dose collapsed across sex are listed in 
Table 3.3, and displayed by dose and sex in the bottom of Figure 3.11.  For both males and 
females, the fewest lights were extinguished after the daytime alprazolam 1mg dose.  
The Digit Symbol Substitution Task (DSST) 
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model analysis revealed 
significant effects of Dose [F(5,60) = 3.0, p = 0.018] and Time [F(12,135) = 4.19, p < .0001)] for 
number of trials attempted.  Likewise, there were significant effects of Dose [F(5,60) = 3.92, p = 
0.004] and Time [F(12,135) = 3.71, p < .0001] for number of correct trials entered.  Typically, 
the fewest trials were attempted and correctly entered after the daytime alprazolam 1mg and the 
bedtime alprazolam 2mg doses.  There was an effect of Sex [F(1,11)] for predictions of how well 
the volunteer thought they would perform prior to task administration (F = 52.15, p < .0001), the 
percentage of correct trials entered (F = 14.60, p = .003), and estimates of how well the volunteer 
thought they did perform immediately after task completion (F = 32.04, p < .0001), with males 
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predicting better performance, entering a greater percentage of correct trials, and retrospectively 
rating better performance than females.  
Emax analysis:  Trough means (SEMs) values for DSST measures that varied 
significantly by dose are listed in Table 3.3.  The only item for which there was a main effect of 
Sex [F(1,11) = 4.96, p = .048] was for the question ‘How well do you think you will perform?’, 
and females proactively estimated their performance would be worse than males (M ± SE
collapsed across dose with “normal performance” scored at 0 and negative numbers indicating 
poorer relative expected performance: [males -2  ± 1.96, females -11.19 ± 1.82]).
The SafeDrive Application 
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model analysis revealed 
no significant effects or interactions for completion time of either the simple visual or simple 
auditory tests, p > .05.  For the complex visual test, there were effects of Sex [F(1,11) = 10.67, p 
= .008] and Time [F(6,72) = 2.28, p = .045] and a Dose x Time interaction [F(60,673) = 1.94, p = 
.003].  Irrespective of dose, females completed the test quicker than males (M ± SE: [males:
524.64 ± 3.10, females: 515.23 ± 4.03]).  For both males and females, completion time was
quickest at the pre-drug baseline and at the first morning timepoint but became slower for the 
next 4hr.  There was an improvement in completion time at the last timepoint.  A similar pattern 
of results was observed for the complex auditory test, with significant effects of Sex [F(1,11) = 
6.73, p = .025] and Time [F(6,72) = 4.50, p = .001].  Irrespective of dose, females completed the 
test quicker than males (M ± SE: [males: 652.28 ± 4.34, females: 644.83 ± 5.72]).  There were no
differences in the failure rate for any the four tests as a function of sex, dose, or time. 
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Emax analysis:  There was a main effect of Dose for peak (i.e., slowest) completion time 
for the simple [F(5,58) = 4.47, p = .002] and complex [F(5,58) = 3.24, p = .012] visual tests.  
Completion times were slowest in the daytime alprazolam 1mg and bedtime alprazolam 2mg 
conditions (see Table 3.3).  
Assessments of Subjective Drug Effect 
Drug Visual Analog Scales (VAS) 
Time course analysis:  Figure 3.12 displays the time course effects for the representative 
VAS questions, ‘Do you feel any drug effects?’ and ‘Do you feel any bad drug effects?’.  Dose 
effects were observed with the daytime alprazolam 1mg dose and bedtime alprazolam 2mg doses. 
For the active bedtime doses, the largest effects were observed at the first morning timepoint 
(~8:30 AM), but after the daytime alprazolam 1mg dose, the largest effects were observed 
approximately 1hr after dosing (~9:30 AM).  Similar dose-related and time-action profiles were 
observed for other VAS measures (e.g., ‘Do you feel high?’ and ‘Does the drug have any sedating 
effects?’).  Sex was a significant factor for ‘Does the drug have any stimulating/arousing effects?’ 
[F(1,11) = 15.74, p = .036] only, with females reporting significantly more stimulating/arousing 
effects than males, though the means were below 1 (out of a possible 100) for both groups (M ±
SE: males 0.37 ± .09, females 0.91 ± .23).  The time-action profile of subjective drug VAS
ratings differed between males and females.  After the daytime alprazolam 1mg dose, females 
reported drug effects longer than males (though this was nonsignificant: Tukey’s post hoc test, p > 
.05).  In contrast, after the bedtime alprazolam 2mg dose, males reported drug effects longer than 
females (though this was nonsignificant: Tukey’s post hoc test, p > .05).  No significant dose 
effects were detected for the items ‘Does the drug have any good effects?’ and ‘Does the drug 
have any stimulating/arousing effects?’.  An AUC analysis by sex was non-significant. 
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Emax analysis:  Items with a significant Dose effect in the two-factor (Sex x Dose) 
model are listed in Table 3.4 and are displayed as a function of dose and sex in Figure 3.13.  Peak 
effects were generally dose-related and highest in the daytime alprazolam 1mg condition.  
The Adjective Checklist 
Time course analysis:  Figure 3.14 displays the time course effects for the representative 
Adjective Checklist items, difficulty concentrating and sleepy.  The largest scores were observed 
after the daytime alprazolam 1mg and bedtime alprazolam 2mg doses.  For items with a 
significant effect of Sex (relaxed, difficulty concentrating, dry mouth, heavy/sluggish, and 
sleepy), females reported greater effects than males (M ± SE: [relaxed: males 0.75 ± 0.04,
females 1.69 ± 0.05], [difficulty concentrating: males 0.12 ± 0.02, females 0.37 ± 0.03], [dry
mouth: males 0.09 ± 0.01, females 0.01 ± 0.00], [heavy/sluggish: males 0.38 ± 0.03, females 0.38
± 0.03], and [sleepy: males 0.86 ± 0.05, females 0.88 ± 0.04]).  An AUC analysis by sex was non-
significant. 
Emax analysis:  Means (SEMs) for items with a significant Dose effect in the two-factor 
(Sex x Dose) model are listed in Table 3.4.  The only Adjective Checklist peak score that differed 
between males and females was lightheadedness [F(1,11) = 4.88, p < .05], with females (0.19 ±
0.06) reporting more lightheadedness than males (0.06 ± 0.04).  Although other peak Adjective
Checklist scores did not vary as a function of Sex, there were differences between males and 
females for specific doses (see Figure 3.15).  Females reported upset stomach and difficulty 
concentrating after the bedtime zolpidem 10mg dose, while males did not. 
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The Observer Adjective Checklist 
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model results are listed 
in Table 3.4.  For the Observer Adjective Checklist items with a significant effect of time 
(relaxed, sleepy, clumsy, sluggish, and dazed/spaced-out), scores were generally higher in the 
morning and tapered off towards the end of the session (see Figure 3.14 for representative 
examples).  Observer Adjective Checklist items with a significant effect of dose (relaxed, sleepy, 
and sluggish) were typically highest for the positive control condition.  Females were rated as 
clumsier than males (M ± SE: males 0.38 ± 0.01, females 0.99 ± 0.01).  As can be seen in Figure
3.14, sluggish scores are higher for the daytime alprazolam 1mg condition for both males and 
females, but the peak occurred earlier for males (1hr post drug administration) than females 
(1.5hr post drug administration).  The effect also appears to be of longer duration in females 
compared to males.  This pattern of results was similar for the item, dazed/spaced-out.  An AUC 
analysis by sex was non-significant. 
Emax analysis:  Means (SEMs) for items with a significant effect of Dose in the two-
factor (Sex x Dose) model are listed in Table 3.4.  Peak Observer Adjective Checklist scores did 
not vary as a function of Sex for any item, p > .05.  
Sleep Measures 
Sleep Visual Analog Scales (VAS)  
In general, volunteers reported that they fell asleep more easily and woke up less often after any 
of the positive bedtime dose administrations.  Volunteers reported feeling most clear-headed after 
the bedtime alprazolam 0.5mg dose (81.63 ± 5.55) and least clear-headed after the bedtime 
alprazolam 2mg dose (43.86 ± 8.57).  While Sleep VAS outcomes were not significantly different
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between males and females, as can be seen in Figure 3.16, males reported more positive sleep 
indices for Sleep VAS items.  
Fitbit 
Two-factor (Sex x Dose) mixed-model analysis revealed no significant effects or interactions for 
total sleep time, see the bottom of Figure 3.16.  Due to equipment malfunction and user error, 
approximately 30% of fitbit data were missing. 
Physiological measures 
Blood pressure 
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model results are 
displayed in the top of Figure 3.17.  For all dose conditions, blood pressure measurements were 
lower for females than males at all timepoints.  Blood pressure decreased slightly 15 min after 
morning drug administration and then generally leveled off near the baseline measurements.  
Blood pressure was unaffected by dose. 
Emax analysis:  There was an effect of Sex [F(1,11) = 21.65 – 22.12, p < .05] for peak 
and trough blood pressure.  Males reached higher peak systolic (M ± SE: [males: 132.94 ± 1.78,
females: 114.96 ± 2.35]) and diastolic (M ± SE: [males: 81.50 ± 0.99, females: 74.83 ± 1.58])
blood pressure than females.  Females reached lower trough systolic blood pressure than males 
(M ± SE: [males: 112.42 ± 1.60, females: 96.02 ± 1.92).
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Heart rate 
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model results are 
displayed in the bottom of Figure 3.17.  Heart rate decreased from baseline until approximately 
2hr after drug administration and then increased to near baseline levels by the end of session.  
Heart rate was unaffected by dose and did not vary significantly by sex (though mean heart rate 
measurements were lower in females than males for all timepoints except the first taken 
approximately 1hr after waking).  
Emax analysis:  There was a main effect of Dose [F(5,58) = 2.96, p = .019] for peak 
heart rate.  The highest heart rate was observed during the daytime alprazolam session (M ± SE:
81.79 ± 2.96) while the mean peak heart rate from the other five sessions was 76.3 ± 3.29 bpm,
but post hoc dose comparison tests were non-significant, p > .05. 
Respiration rate
Time course analysis:  Three-factor (Sex x Dose x Time) mixed-model analysis revealed 
significant effects of Sex on respiration rate measured over 60 seconds [F(1,11) = 9.57, p = .01], 
with females breathing slightly slower than males (M ± SE: [males: 16.17 ± 0.19, females: 15.06
± 0.06]).  Neither dose nor time significantly affected respiration rate, p > .05.
Emax analysis:  There were no main effects or interactions for respiration rate when 
analyzed as a peak or trough value, p > .05. 
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Table 3.1 Subject demographics and baseline characteristics 
Mean (SEM) 
  Males (n = 6) Females (n = 8) 
Age   26.83  (2.02)   33.50   (3.43) 
Height (in)   70.58  (1.36)   66.86   (0.95) 
Weight (lb) 176.00  (8.47) 150.75 (10.21) 
BMI   24.92  (1.45)   23.68   (1.43) 
Body Fat Percentage   23.75  (2.68)   34.43   (3.49) 
Years of Education   15.67  (0.99)   16.25   (0.96) 
WRAT   50.33  (1.98)   50.88   (0.52) 
SCL-90     9.00  (5.29)     9.86   (3.20) 
Beck     2.00  (0.58)     2.00   (0.80) 
PSQI     6.00  (1.35)     4.25   (0.84) 
MAST     2.83  (0.98)     2.38   (0.89) 
30-Day Alcohol Use     5.50  (2.01)     8.50   (2.39) 
Bolded values indicate a significant difference between males and females with 
t-test statistic, p < .05. 
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Table 3.2 Standard deviation of lane position (SDLP) descriptive statistics from baseline drives 
of all six sessions  
 Whole Drive  Highway Section 
 
Mean Range 
Variance 
(s2)  Mean Range 
Variance 
(s2) 
Males (n = 6)        
  1 28.45 26.19 – 30.37   2.54  19.07 15.94 – 25.03   11.73 
  2 39.38 34.52 – 44.81 17.57  21.99 17.61 – 28.59   19.17 
  3 30.73 28.70 – 33.14   3.57  18.46 11.84 – 28.71   33.48 
  4 37.73 33.31 – 43.15 12.76  27.22 18.67 – 32.73   24.69 
  5 36.92 35.87 – 38.11   0.84  22.26 11.05 – 40.17   93.10 
  6 30.26 27.65 – 34.06   6.44  19.03 13.28 – 28.01   26.91 
Average 33.91  7.29  21.34  34.85 
        
Females (n = 8)        
  7 43.11 37.84 - 49.61 20.28  22.43 14.13 – 30.04   31.28 
  8 30.42 27.4 - 32.36   2.83  25.26 22.33 – 27.72     4.04 
  9 41.17 34.7 - 49.68 26.33  34.68 24.14 – 50.75 125.89 
10 38.11 35.5 - 41.10   4.57  21.67 12.55 – 33.48   64.38 
11 32.56 27.6 – 39.96   9.50  25.14 17.92 – 31.87   34.74 
12 42.56 39.4 - 47.00   6.73  33.36 26.61 – 37.99   23.29 
13 30.29 27.8 - 35.04   7.45  23.93 11.63 – 36.55   80.10 
14 31.15 25.6 - 35.33 13.02  11.76 9.59 – 14.45     3.35 
Average 36.17  11.34  24.78  45.88 
        
Total (n = 14)        
Average 35.20  9.60  23.30  41.15 
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Table 3.3 Emax (peak and trough) values for psychomotor and related subjective assessments 
Dose (mg) Combination (Bedtime/Daytime) 
F(5,58) PLC/PLC Z(10)/PLC PLC/A(1.0) A(0.5)/PLC A(1.0)/PLC A(2.0)/PLC 
Driving Simulator 
     Standard deviation of lane position 8.90 1.32 (0.08) 1.48 (0.12) 1.71   (0.08) 1.33 (0.06) 1.35 (0.06) 1.56 (0.09) 
 Number of lane departures 6.65 18.07 (1.26) 20.50 (1.93) 28.00   (2.18) 18.14 (1.15) 19.36 (1.39) 22.07 (1.82) 
   Time departed from lane (%) 8.44 5.35 (0.63) 7.31 (1.62) 10.21   (1.14) 5.27 (0.50) 6.01 (0.76) 7.82 (1.09) 
Driving Visual Analog Scales 
   Driving was difficult 3.76 14.29 (5.96) 20.29 (8.21) 44.07 (10.20) 14.86 (7.04) 26.64 (9.30) 31.79   (8.58) 
 I performed well (T) 2.55 62.86 (7.08) 67.86 (7.92) 49.43   (8.25) 73.71 (6.72) 63.86 (8.25) 64.57   (6.82) 
 I could drive safely (T) 4.21 79.36 (8.25) 76.64 (8.80) 48.07   (9.69) 79.71 (7.95) 64.29 (8.84) 65.07 (10.54) 
Simulator Sickness Questionnaire 
 Oculomotor 7.51 1.57 (0.43) 1.86 (0.58) 4.57   (0.89) 1.36 (0.50) 2.71 (0.67) 3.07 (0.82) 
  Disorientation 3.07 0.64 (0.25) 0.86 (0.35) 2.21 (0.59) 1.21 (0.55) 1.1 (0.40) 0.57 (0.25) 
SafeDrive Application (time, ms) 
  Simple visual test 4.47 362 (20.53) 364 (20.26) 405 (19.50) 371 (22.63) 390 (26.22) 407 (30.51) 
  Complex visual test 3.24 566 (28.42) 558 (18.76) 599 (19.12) 557 (13.09) 561 (12.71) 615 (26.60) 
Circular Lights Task 
  Lights extinguished 7.48 77.71 (3.21) 78.21 (2.16) 67.36   (2.65) 79.07 (2.05) 75.43 (1.85) 69.64 (2.52) 
Digit Symbol Substitution Task 
  How well do you think you will 
  perform? (T) 4.69 9.29 (3.21) 8.14 (2.54) 6.00   (2.20) 7.50 (2.22) 10.64 (3.37) 6.21 (2.37) 
  Trials attempted (T) 8.29 41.29 (1.22) 41.86 (1.08) 39.86   (1.16) 41.29 (1.17) 40.71 (1.05) 39.50 (1.24) 
  Number of correct trials (T) 8.66 40.43 (1.17) 40.64 (1.01) 39.21   (1.19) 40.50 (1.20) 40.29 (1.09) 38.79 (1.25) 
  Percent of correct trials (T) 2.85 92.32 (1.02) 90.99 (1.40) 86.67 (2.89) 92.54 (1.16) 90.94 (1.55) 88.06 (2.47) 
PLC = placebo, Z = zolpidem, A = alprazolam.  Data are means (SEMs) collapsed across sex. Two factor analysis (Sex x Dose) detected significant main effects 
of Dose for all items listed, p < .05. Items marked with (T) indicate trough scores are shown; all other items are peak.  Bolded values indicate a significant Tukey 
post hoc test from the placebo/placebo dose combination, and boxed items indicate a significant Tukey post hoc test from the zolpidem/placebo condition, p < .05. 
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Table 3.4 Emax (peak and trough) values of subjective and observer-rated measures 
Dose (mg) Combination (Bedtime/Daytime) 
F(5,58) PLC/PLC Z(10)/PLC PLC/A(1.0) A(0.5)/PLC A(1.0)/PLC A(2.0)/PLC 
Drug Visual Analog Scales 
     Any Drug Effect 8.80 13.86 (5.32) 20.07 (6.11) 49.14 (8.59) 11.29 (4.77) 25.71 (5.77) 41.00 (6.72) 
     High 2.98 8.29 (4.44) 8.64 (4.54) 28.71 (7.96) 4.29 (2.33) 9.71 (5.29) 11.79 (4.43) 
     Bad Effects 7.12 2.71 (1.48) 12.07 (3.65) 34.71 (7.68) 5.64 (3.06) 13.64 (5.94) 20.07 (6.41) 
     Sedating Effects 6.80 13.00 (5.40) 16.43 (4.92) 51.57 (8.58) 13.14 (5.36) 29.29 (8.14) 38.07 (8.83) 
Adjective Checklist 
     Dizzy 2.52 0.07 (0.07) 0.07 (0.07) 0.36 (0.17) 0.07 (0.07) 0.07 (0.07) 0.07 (0.07) 
     Upset Stomach 3.27 0.00 (0.00) 0.36 (0.17) 0.07 (0.07) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
     Drunken 2.76 0.07 (0.07) 0.14 (0.10) 0.07 (0.07) 0.14 (0.14) 0.36 (0.17) 0.50 (0.20) 
     Slurred Speech 3.90 0.00 (0.00) 0.00 (0.00) 0.50 (0.20) 0.07 (0.07) 0.21 (0.11) 0.21 (0.11) 
     Difficulty Concentrating 7.31 0.29 (0.13) 0.57 (0.23) 1.43 (0.31) 0.50 (0.20) 0.79 (0.28) 1.14 (0.25) 
     Heavy/Sluggish 8.51 0.43 (0.17) 0.86 (0.18) 1.71 (0.30) 0.64 (0.17) 1.07 (0.30) 1.93 (0.30) 
     Sleepy 6.74 1.29 (0.29) 1.36 (0.27) 2.57 (0.29) 1.64 (0.27) 2.29 (0.34) 2.50 (0.27) 
     Weak 5.34 0.07 (0.07) 0.29 (0.13) 0.79 (0.28) 0.14 (0.10) 0.29 (0.16) 0.86 (0.29) 
     Uncoordinated 4.11 0.29 (0.13) 0.43 (0.14) 1.00 (0.31) 0.36 (0.17) 0.50 (0.17) 0.71 (0.22) 
Observer Adjective Checklist 
     Sleepy 2.63 1.64 (0.17) 1.36 (0.23) 2.21 (0.26) 1.57 (0.20) 1.50 (0.17) 2.00 (0.26) 
     Clumsy 2.86 0.36 (0.17) 0.07 (0.07) 0.71 (0.19) 0.29 (0.16) 0.14 (0.10) 0.57 (0.17) 
     Sluggish 3.72 0.86 (0.18) 0.86 (0.23) 1.93 (0.35) 1.07 (0.22) 1.21 (0.19) 1.14 (0.23) 
PLC = placebo, Z = zolpidem, A = alprazolam.  Data are means (SEMs) collapsed across sex. Two factor analysis (Sex x Dose) detected significant main 
effects of Dose for all items listed, p < .05. Items marked with (T) indicate trough scores are shown; all other items are peak. Bolded values indicate a 
significant Tukey post hoc test from the placebo/placebo dose combination, and boxed items indicate a significant Tukey post hoc test from the 
zolpidem/placebo condition, p < .05. 
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In-Person Screening Visit 
n = 48 
Enrolled 
n = 22 
Volunteer withdrew (n = 9) 
Medically disqualified (n = 8) 
Lost contact (n = 4) 
Withdrew Before 
First Admission 
n = 5 
Study Completion 
n = 14 
Early Termination 
n = 3 
Figure 3.1 Participant flow 
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Figure 3.2 Baseline drive standard deviation of lane position (SDLP) variability across all 
six study sessions.  Each point represents the SDLP (from the whole drive [top row] or the 
highway section of the drive [bottom row]) of a volunteer’s first drive (pre-drug administration 
baseline) of each of the six study sessions.  Points clustered closer together in a column (e.g., 
Volunteer 14) indicate less variability in SDLP from one session to the next than for points more 
spread out (e.g., Volunteer 13). 
Figure 3.2 Baseline Drive Standard Deviation of Lane Position (SDLP) Variability Across 
Six Study Sessions.  
Males
1 2 3 4 5 6
 0
24
28
32
36
40
44
48
52
Volunteer
C
en
tim
et
er
s (
cm
)
Females
7 8 9 10 11 12 13 14
5
10
15
20
25
30
35
40
45
50
55
 0
C
en
tim
et
er
s (
cm
)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
A. Whole Drive SDLP 
B. Highway Section SDLP
Males Females
 78 
Age
V
ar
ia
nc
e 
s2
0
5
10
15
20
25
30
20 25 30 35 40 45 50
0
25
50
75
100
125
150
V
ar
ia
nc
e 
s2
Age
20 25 30 35 40 45 50
Males: r = .70
Females: r = .58
Males
Females
Highway Section
Whole Drive
Males: r = -.15
Females: r = .66
Figure 3.3 Variance in baseline drive standard deviation of lane position (SDLP) correlation 
with age.  n = 14 (6 male).  Data are individual volunteer variance in SDLP (from the whole 
drive [top row] or the highway section of the drive [bottom row]) calculated from the first drive 
(pre-drug administration baseline) of each of the six study sessions displayed as a function of age 
and sex.  Pearson correlations were non-significant, p > .05, both when analyzing sexes 
separately and together.  
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Figure 3.4 Standard deviation of lane position change from placebo for each volunteer 
across all active dose conditions, from 8.5hr to 11.5hr after bedtime drug administration.  
Each symbol represents a single volunteer’s drive at the corresponding dose and timepoint. 
Significant impairment (equivalent to ³ .05% BAC) based on symmetry analysis is indicated by
boxes [black boxes indicate the dose was impairing for the group as a whole (n = 14); red boxes 
indicate impairment for females (n = 8) analyzed alone; blue boxes indicate impairment for males 
(n = 6) analyzed alone], p < .05.  Sex-specific boxes are only pictured when whole group 
outcomes were not consistent with sex-collapsed outcomes. * Indicates impairment equivalent to 
³ .08% BAC.  ** Indicates impairment equivalent to ³ .10% BAC.
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Figure 3.5 Driving simulator outcomes measured across the whole drive, from pre-drug 
baseline (BL) through the end of the 5hr session. n = 14 (6 males).  Data are means (SEM) and 
are displayed as a function of dose (mg), time, and sex (males in left column, females in right 
column).  Time course analyses indicated main effects of Dose [F(5,60) = 3.72 - 4.13, p < .05] 
and Time [F(6,72) = 2.26 - 8.82, p < .05] and a Dose by Time interaction [F(30,360) = 2.47 - 
3.08, p < .005] for standard deviation of lane position (SDLP) and percent of drive departed from 
lane.  There was a main effect of Sex for standard deviation of speed [F(1,11) = 24.71, p < 
.0001], with females varying speed significantly less than males (Tukey’s post hoc test, p < .05).
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Figure 3.6 Mean peak (standard deviation of lane position [SDLP], time departed from 
lane, total lane departures) and trough (speed) effects for driving simulator outcomes.  n = 
14 (6 males).  Data are means (SEM) and are displayed as a function of dose (mg) and sex.  Dose 
combinations below each graph are shown with the bedtime dose listed above the daytime dose 
(PLC = placebo, A = alprazolam, Z = zolpidem).  Two factor analyses (Dose x Sex) detected a 
significant main effect of Dose [F(5,58) = 6.65 – 8.44, p < .0001] for peak SDLP, time departed 
from lane, total lane departures and a Sex by Dose interaction for trough speed [F(5,58) = 3.36, p 
= .01].  * Indicates a significant peak effect of dose compared to placebo (Tukey’s post hoc test, p 
< .05). 
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Figure 3.7 Time course of mean driving visual analog scale (VAS) outcomes, from pre-drug 
baseline (BL) through the end of the 5hr session.  n = 14 (6 males).  Three-factor (Sex x Dose 
x Time) analyses revealed a main effect of Time [F(6,72) = 3.48 – 711.19, p < .005] for all three 
items.  For the items “Driving was difficult” and “I could drive safely in a real car right now,” 
there was also a main effect of Dose [F(5,60) = 2.76 - 3.41, p < .05] and a Dose by Time 
interaction [F(3,360) = 1.83 – 2.46, p < .01).   
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Figure 3.8 Mean Emax of driving simulator visual analog scale (VAS) outcomes.  n = 14 (6 
males).  Data are means (SEM) and are displayed as a function of dose (mg) and sex.  Dose 
combinations below each graph are shown with the bedtime dose listed above the daytime dose 
(PLC = placebo, A = alprazolam, Z = zolpidem).  Two factor analyses (Dose x Sex) detected a 
significant main effect of Dose [F(5,58)] for peak response to “driving was difficult,” [F = 3.76, p 
= .005] and trough response to “I could drive safely in a real car right now” [F = 4.21, p = .003]. 
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Figure 3.9 Mean time course of simulator sickness questionnaire subscale scores, from pre-
drug baseline (BL) through the end of the 5hr session.  n = 14 (6 males).  Three-factor (Sex x 
Dose x Time) analyses revealed main effects of Sex [F(1,11) = 13.67 - 19.70, p < .005], Dose 
[F(5,60) = 2.50 – 7.22, p < .05], and Time [F(6,72) = 9.17 – 16.22, p < .0001], and a Sex x Time 
[F(6,72) = 3.37 – 4.19, p < .01], interaction for all three subscales.  
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Figure 3.10 Mean Emax simulator sickness questionnaire subscale scores.  n = 14 (6 males).  
Data are means (SEM) and are displayed as a function of dose (mg) and sex.  Dose combinations 
below each graph are shown with the bedtime dose listed above the daytime dose (PLC = 
placebo, A = alprazolam, Z = zolpidem).  Two factor analyses (Sex x Dose) detected a significant 
main effect of Dose [F(5,58) = 2.03 – 7.51, p < .05] for oculomotor discomfort and disorientation 
subscales.  * Indicates a significant peak effect of dose compared to placebo (Tukey’s post hoc 
test, p < .05). 
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Figure 3.11 Mean time course and Emax outcomes for the circular lights task.  n = 14 (6 
males).  Data are means (SEM) and are displayed as a function of dose (mg), time (top row only), 
and sex.  Time course (top row): Time course analyses indicated main effects of Dose [F(5,60) = 
3.61, p = .006] and Time [F(12,135) = 5.76, p < .0001] and a Dose x Time interaction [F(60,674) 
= 1.64, p = .002] for number of lights extinguished. Emax (bottom row): Emax = fewest lights 
extinguished during a single session.  Dose combinations below the graph are shown with the 
bedtime dose listed above the daytime dose (PLC = placebo, A = alprazolam, Z = zolpidem).  
Two factor analyses (Dose x Sex) detected a main effect of Dose [F(5,58) = 7.48, p < .001].  * 
Indicates a significant peak effect of dose compared to placebo (Tukey’s post hoc test, p < .05).
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Figure 3.12 Time course of mean visual analog scale (VAS) ratings of the subjective 
measures ‘Do you feel any drug effects?’ and ‘Do you feel any bad drug effects?’ after drug 
administration, from pre-drug baseline (BL) through the end of the 5hr session.  n = 14 (6 
males).  Data are means (SEM) and are displayed as a function of dose (mg), time, and sex.  Time 
course analyses indicated main effects of Dose [F(5,60) = 4.11 - 4.76, p < .005] and Time 
[F(12,135) = 5.64 - 11.69, p < .0001] and a Dose by Time interaction [F(60,674) = 2.12 - 3.00, p 
< .0001] for both measures.  Filled symbols indicate mean ratings that were significantly different 
from placebo at that timepoint within sex (Tukey’s post hoc test, p < .05). 
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Figure 3.13 Mean peak ratings for representative visual analog scale (VAS) items.  n = 14 (6 
males).  Data are means (SEM) and are displayed as a function of dose (mg) and sex.  Dose 
combinations below each graph are shown with the bedtime dose listed above the daytime dose 
(PLC = placebo, A = alprazolam, Z = zolpidem).  Two factor analyses (Dose x Sex) detected a 
significant main effect of Dose [F(5,58) = 6.80 – 8.80, p < .0001] for all three items.  * Indicates 
a significant peak effect of dose compared to placebo (Tukey’s post hoc test, p < .05).  
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Figure 3.14 Time course of mean adjective and observer adjective checklist ratings for the measures 
difficulty concentrating, sleepy, relaxed, and sluggish.  n = 14 (6 males). Data are means (SEM) and are 
displayed as a function of dose (mg) and sex.   Time course analyses indicated main effects of Dose [F(5,60) = 
3.35 - 4.12] and Time [F(60,674) =6.94 - 22.15] for all four items, p < .05.  A main effect of Sex [F(1,11) = 
3.35 - 6.97, p < .05] was found for all items except relaxed.  
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Figure 3.15 Mean peak ratings for representative adjective checklist items upset stomach, 
difficulty concentrating, heavy/sluggish, and sleepy.  n = 14 (6 males).  Data are means (SEM) 
and are displayed as a function of dose (mg) and sex.  Dose combinations below each graph are 
shown with the bedtime dose listed above the daytime dose (PLC = placebo, A = alprazolam, Z = 
zolpidem).  Two factor analyses (Dose x Sex) detected a significant main effect of Dose [F(5,58) 
= 3.27 – 8.51, p < .02] for all four items.  * Indicates a significant peak effect of dose compared 
to placebo (Tukey’s post hoc test, p < .05).  A Sex x Dose interaction was detected for upset 
stomach [F(5,58) = 3.15, p = .014]. 
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Figure 3.16 Sleep outcomes from visual analog scale (VAS) ratings and fitbit measurement.  
n = 14 (6 males) for VAS and n = 9 (4 males) for fitbit.  Data are means (SEM) and are displayed 
as a function of dose (mg) and sex.  Dose combinations below each graph are shown with the 
bedtime dose listed above the daytime dose (PLC = placebo, A = alprazolam, Z = zolpidem).  
Two factor (Dose x Sex) analyses detected a significant main effect of Dose [F(5,59)] for the 
VAS items “I feel asleep easily last night” (F = 2.89, p = .021), “I woke up clear-headed this 
morning” (F = 4.85, p = .001), “I woke up often last night” (F = 5.47, p < .0001), and total time 
slept (F = 3.23, p = .012). 
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Figure 3.17 Time course of blood pressure and heart rate, from 45min before the daytime 
drug administration through the end of the 5hr session. n = 14 (6 males).  Data are means 
(SEM) collapsed across the six drug conditions as time course analyses indicated no effect of 
dose on any physiological outcome measure, p > .05.  Time course analyses indicated significant 
main effects of Sex [F(1,11) = 36.37 – 231.94, p < .0001] for systolic and diastolic blood 
pressure, and Time [F(11,123) = 2.11 – 6.70, p < .05] for systolic and diastolic blood pressure 
and heart rate. 
 
 93 
 
 
 
 
 
CHAPTER V. DISCUSSION 
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This study used a sophisticated driving simulator to examine the next-day pharmacodynamics 
(specifically related to driving impairment) of bedtime-administered alprazolam in men and 
women.  The results provided support for the primary study hypothesis.  Detrimental effects on 
simulated driving performance were evident up to 13.5hr after bedtime alprazolam 2mg 
administration, and the increase in SDLP was equivalent to that exhibited by persons with a 
0.08% - 0.10% BAC up to 12.5hr after administration.  The objective driving impairment was 
corroborated by decrements on other psychomotor task performance, including the Circular 
Lights Task and Digit Symbol Substitution Task.  Volunteers were unaware of their own degree 
of impairment after the bedtime alprazolam 2mg dose and rated their ability to drive safely non-
differently than placebo.  Even after the positive control, volunteers rated their ability to drive 
safely around 60 (out of 100) near the time of peak drug effect (1.5hr post drug administration).  
At that dose, volunteers displayed impairment equivalent to and greater than that seen at a 0.10% 
BAC, providing support of the hypothesis that persons are unaware of their own degree of 
impairment.   
 
The profile of effects varied somewhat between the sexes, but not always in a consistent or 
definitive pattern, and caution should be taken when interpreting these results.  Group sizes were 
small (8 females and 6 males), making this study underpowered to detect and fully characterize 
possible sex differences in pharmacodynamics.  Females did display greater impairment and 
report more symptoms after administration of the zolpidem 10mg dose, and this is consistent with 
previous literature (Bocca et al. 1999, Verster et al. 2002a, Leufkens et al. 2009, Verster and Roth 
2012b) and with the FDA decision to reduce starting doses of zolpidem in women (FDA 2013c).  
Females also generally reported more effects related to simulator sickness, which is consistent 
with previous reports (Park and Hu 1999, Klüver et al. 2015).  Males reported more subjective 
effects after the bedtime alprazolam 2mg dose and also displayed a more consistent pattern of 
SDLP impairment than females, which was not hypothesized.  
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The primary outcome measure, SDLP, was sensitive to the impairing effects of the positive 
control.  This confirms that SDLP was a valid measure and provides confidence that the increase 
in SDLP observed after test doses are indicative of true impairment.  Not all driving simulator 
outcome measures were sensitive to the positive control.  These included reaction time measures 
to incursion events.  Because the same simulation was used for each test drive, this could be a 
function of practice and predictability (e.g., the volunteer knows that a pedestrian will walk out 
into the road immediately after they pass the red truck, so they can decelerate in anticipation).  
This anticipatory behavior was demonstrated frequently in the current study.  Varying the 
location of the incursion events would provide a more effective measure of reaction time to 
unexpected events and would also be a more naturalistic experience.  As increased variability is 
introduced into the simulations, the trade-off between maximizing experimental control and 
maintaining external validity must be considered.   
 
The driving simulator task appeared to be the most sensitive to drug-induced impairment.  The 
other simple laboratory measures of cognitive and psychomotor impairment tended to show dose 
effects and significant differences between positive control and placebo, but this was not always 
the case.  One test method that did not appear sensitive to drug effects was the SafeDrive 
Application.  This is unfortunate as it is currently being used by the Italian police force as a 
sobriety test in cases of suspected drugged driving.  The lack of effect seen here could be due to 
the repeated nature of the study – volunteers performed the task many times.  In the field, a 
suspected drugged driver would perform the task once and would not have the benefit of multiple 
practices.  It should be noted that the pass rate of the four tests ranged from 66% for the simple 
auditory test to 82% for the complex visual test, and the percentage of volunteers who passed or 
failed the tests did not significantly differ by dose.  This could mean that 34 to 18% of 
unimpaired drivers may fail one or more tests if this is used as a roadside sobriety measure.  
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These false-positive rates are lower than what been reported for the battery of field sobriety tests 
used in the United States.  The Standardized Field Sobriety Test (SFST) is a battery of three tests 
(horizontal gaze nystagmus, the walk-and-turn, and the one-leg stand tests) performed during a 
traffic stop in order to determine if a driver is impaired.  When properly administered, these tests 
have been found to be over 90% accurate in identifying alcohol-impaired drivers (Stuster and 
Burns 1998).  Given these discrepancies in false positives, a more sensitive and accurate measure 
of drug-impaired driving is needed.  
 
A finding with possible implications for future drugged driving studies was that SDLP variability 
in baseline drives was related to age.  Older volunteers displayed greater baseline SDLP 
variability than younger volunteers (i.e. the SDLP measured during the first drive of each session 
was less consistent for older volunteers from one session to the next).  If this association is real 
(in that it exists in the population as a whole and that older drivers are less consistent in the 
amount of lateral deviation they engage in while driving), it could have important implications for 
future results obtained from this type of driving simulator study.  There are two possible 
interpretations to this association.  First, it could mean that this type of driving simulator study is 
not as useful for characterizing drug effects on driving performance in older persons because their 
baseline and/or placebo drives are not stable.  Even in the within-subject design of the study, for a 
volunteer to serve as their own control, that control condition must be stable and meaningful.  
Meaningful comparison of SDLP across multiple test conditions and days is most valid if SDLP 
is stable from one day to the next.  The second interpretation is that this type of study may be 
particularly sensitive in older drivers because it can capture day-to-day differences in baseline 
SDLP and what impact drugs may have on overall SDLP.  A change from baseline analysis may 
be more appropriate (instead of a comparison to placebo) to account for the larger day-to-day 
variability in baseline SDLP in older volunteers.  
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The lack of consistent performance in the driving simulator displayed by older volunteers could 
be due to their relative inexperience with virtual reality environments (e.g., video games).  If that 
is the case, then additional practice beyond what was provided in the current study may be a 
solution.  Before the baseline drive of the first session, volunteers had used the simulator at least 
seven times (totaling over an hour of drive time), and a practice drive was performed at the 
beginning of each session to re-familiarize the volunteer with the simulator prior to data 
collection.  Baseline drive SDLP variability between sessions tended to decrease for the last two 
sessions compared to the first two sessions in the oldest study volunteers, so there is evidence that 
practice can reduce SDLP variability.  It should be noted that by the start of the fifth session, each 
volunteer had logged over 6.5hr of drive-time on the simulator.  Instead of standardizing the 
amount of practice each volunteer gets with the simulator, an alternative approach would be to 
allow the volunteer to practice until a target outcome based on SDLP variability between drives is 
achieved (or they reach some pre-determined limit on number of attempts and are disqualified).   
 
Major strengths of this study include the double-blind, placebo-controlled design, administration 
of multiple doses of alprazolam, and inclusion of two positive control doses.  Inclusion of body 
fat percentage as a covariate was another strength of the study design, but body fat was measured 
once and assumed to remain stable.  Because the study took place over a period of weeks (and 
months in some cases), this may not have been the case.  A few volunteers experienced 
significant weight fluctuations during the study, and this may have confounded the results.  A 
more accurate method would have been to measure body fat percentage at each session.  
 
The profile of effects varied between the sexes, but caution should be taken when interpreting 
these results.  Group sizes were small (8 females and 6 males), making this study underpowered 
to detect and fully characterize possible sex differences in pharmacodynamics.  Sample sizes 
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were too small to explore effects of birth control method or menstrual cycle phase.  This study 
was performed in a driving simulator, an artificial environment in which there is no real 
consequence of crashing.  Conscientious driving was incentivized in the current study with 
performance-based bonuses for following the rules of the road during each simulation; 
nevertheless, the absence of real risk could alter participant decision making.  Because the 
primary outcome measure was not a measure of risk, but of an unconscious and automatic 
behavior, it is unlikely to have been influenced by altered decision making.   
 
Future studies should seek to further characterize alprazolam effects in other volunteer 
populations (e.g., older persons, smokers, etc.).  Alprazolam clearance has been shown to increase 
by up to 50% in cigarette smokers (Pfizer 2011) and effects of other nicotine products on 
alprazolam pharmacokinetics are not well characterized.  Although the use of drug concentrations 
in blood as a marker of impairment is imperfect, future studies could collect blood samples and 
correlate alprazolam concentrations with driving impairment.  Additional field sobriety tests (e.g., 
walk in a straight line, recite the alphabet backwards, etc.) could also be incorporated into future 
study designs in order to determine which are most sensitive to drug impairment and possibly 
inform law enforcement procedures in cases of suspected drugged-driving.  
 
While non-drug-using volunteers are the population expected to be most sensitive to drug effects 
(and were therefore the most appropriate group for this study), future studies should explore how 
the development of tolerance affects next-day driving impairment after bedtime alprazolam 
administration.  Characterization of tolerance to drug effects can be methodologically challenging 
as there are many factors to consider.  Multiple types of tolerance can develop in response to 
repeated drug exposure, and each can have differential effects on drug-induced impairment.  
Tolerance to benzodiazepine effects (thought to be mediated at the molecular level by adaptations 
in the GABAA receptor and/or changes to the glutamatergic system (Bateson 2002, Allison and 
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Pratt 2003) occur at different rates.   Assessment of tolerance effects could be accomplished by 
enrolling a patient sample or by administering repeated doses of alprazolam to healthy volunteers.  
The effect of the underlying disease may confound results when studying a patient sample, and 
this could be particularly salient for a sample of insomniacs because sleep deprivation and 
sleepiness have significant detrimental effects on driving performance and related skills 
(Williamson and Feyer 2000, Vakulin et al. 2007, Shekari Soleimanloo et al. 2017).  Driving 
performance of patients with insomnia has been the subject of a few studies.  
 
Perrier and colleagues compared driving performance of 21 untreated insomnia patients and 16 
healthy volunteers on a 1hr monotonous highway driving simulator test and reported that 
insomnia patients had a significantly larger SDLP than healthy controls.  Interestingly, total sleep 
time and self-reported sleepiness scores did not significantly differ between groups, suggesting a 
separate mechanism of driving impairment in insomniacs (Perrier et al. 2014).  This study 
compared SDLP across groups and not within-subject and enrolled untreated insomnia patients.  
 
In an evaluation of zolpidem effects on driving ability 5.5hr after administration in insomniac 
women, Partinen and colleagues reported no significant impairment in SDLP compared to 
placebo (Partinen et al. 2003); however, that result was based on ANOVA testing (known to be 
insensitive to pharmacodynamic effects).  Without access to the raw data, it is impossible to 
determine if the results would be significant using the more appropriate symmetry analysis.  The 
group SDLP means for the placebo and zolpidem conditions were 34cm and 39cm, respectively 
(Partinen et al. 2003), suggesting that impairment was present and significant.  A SDLP increase 
of 5cm is consistent with impairment equivalent to a 0.10% BAC.   
 
On-the-road driving performance of 42 insomnia patients prescribed hypnotics (22 frequent users 
[at least 4 nights per week for more than 3 months] and 20 infrequent users [≤ 3 nights per week]) 
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and 21 healthy, age-matched controls was compared in a single highway driving test (Leufkens et 
al. 2014a).  The night before the test, the frequent hypnotic users were instructed to ingest their 
own prescribed hypnotic, and the infrequent hypnotic users and controls did not ingest any sleep 
medication.  No differences in SDLP were reported between the three groups, but there was no 
within-subject comparison to placebo.  Volunteers were between the ages of 52 – 71, and results 
may only be applicable to similar-aged persons.  A subsample of these volunteers (16 frequent 
hypnotic users, 16 infrequent hypnotic users, 16 healthy controls) participated in a double-blind, 
placebo-controlled, crossover study exploring the effects of bedtime zopiclone 7.5mg on driving 
performance 10-11hr after administration (Leufkens et al. 2014b).  Zopiclone significantly 
impaired driving in all groups.  The SDLP increases from placebo were related to hypnotic 
experience—1.6cm (frequent users), 2.1cm (infrequent users), and 3.6cm (healthy controls)—and 
may be explained by the development of tolerance to the impairing effects of zopiclone.   
 
Final Conclusions 
This is the first study to provide evidence that alprazolam can produce impairment in driving 
performance up to 13.5hr after its administration.  The only dose to show significant impairment 
was 2mg, which is a large dose and unlikely to be prescribed to a patient for sleep disturbances.  
Nevertheless, it provides proof-of-principle that the impairing effects of alprazolam effects can be 
long-lasting.  With a larger sample size and more statistical power, it is possible that impairing 
effects would become evident for the lower doses.    
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Appendix 1: FARS Data Query Details 
 
Step 1*: Choose a year to Query (2007 -2016) 
Step 2*: Choose the Tables to Query 
Option 1 – Crash/Person  
Step 3: Choose the Variables to Use 
All relevant variables are listed under “Person Fields.”  
Step 4: Choose Condition Criteria 
Step 5: Choose Report Form Options 
 
*Steps 1 and 2 are identical for all queries.  
 
Additional query details for Table 1.2 outcomes: 
Step 3: Choose the Variables to Use:  
Person Type 
Alcohol Test Status  
Alcohol Test Results 
 
Step 4: Choose Condition Criteria: 
Person Type: (1) Driver of a Motor Vehicle in Transport 
Alcohol Test Status: All  
Alcohol Test Results: All 
 
Step 5: Cross tabulation of Alcohol Test Status by Alcohol Test Results  
 
Additional query details for Table 1.3 outcomes: 
Step 3: Choose the Variables to Use:  
Person Type 
Drug Test Status  
Drug Test Results (1) 
 
Step 4: Choose Condition Criteria: 
Person Type: (1) Driver of a Motor Vehicle in Transport 
Drug Test Status: All  
Drug Test Results (1): All 
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Step 5: Cross tabulation of Drug Test Status by Drug Test Results (1)  
 
Additional query details for Table 1.4 outcomes: 
Step 3: Choose the Variables to Use:  
Person Type 
Drug Test Status  
Drug Test Results (1) 
Drug Test Results (2) 
Drug Test Results (3) 
 
Step 4: Choose Condition Criteria: 
Person Type: (1) Driver of a Motor Vehicle in Transport 
Drug Test Status: All  
Drug Test Results (1): All 
Drug Test Results (2): All 
Drug Test Results (3): All 
 
Step 5: Case Listing of Drug Test Results (1), Drug Test Results (2), and Drug Test Results (3) performed 
to output all drug test results available listed for each driver involved in a fatal crash. 
 
For data specifically relating to drivers killed in an accident, the additional variable “Injury Severity” must 
be selected under “Person Fields” in Step 3. The condition selected in Step 4 is Injury Severity: (3) Killed.  
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Appendix 2: Complete Study Inclusion and Exclusion Criteria 
Inclusion criteria: 
1. Medical clearance by study physician
2. English-speaking and literate
3. Age is 18 to 50 years old
4. BMI approximately less than or approximately equal to 30
5. UDS results on session days negative for all drugs
6. Negative pregnancy test
7. Willing to participate in all study procedures, including 6 overnight sessions (across approx. 3-6
weeks)
8. Valid driver’s license
9. Signed screening and main study consent
Exclusion criteria 
1. Reports recent use of benzodiazepines or sleeping medications (i.e., past 60 days)
2. Last 30-day history of moderate to severe substance use disorder (excluding caffeine and binge
alcohol use)
3. History of hypersensitivity (e.g., allergy, adverse events) to benzodiazepines
4. Score greater than 2 on Fagerstrom Test for Nicotine Dependence
5. Requires ongoing prescription medication (aside from oral birth control pills)
6. History of clinically significant seizures or head trauma
7. Significant ongoing medical problems (e.g., hypertension, diabetes, asthma)
8. Clinically significant abnormal ECG
9. Clinically significant abnormal liver function results
10. History of AIDS-defining illness
11. Women who are pregnant, lactating, or planning to become pregnant
12. Current acute pain conditions (e.g., recent surgery or wounds)
13. History of Acute Narrow Angle Glaucoma
14. Intolerance to simulated driving environment (e.g. vomiting, extreme vertigo)
15. Current ongoing psychiatric disorder (e.g., schizophrenia, bipolar disorder)
16. Recent use of any agent acting as an inhibitor or inducer of P450 3A4 that would affect study
session outcomes
17. Physical dependence on benzodiazepines, barbiturates, opioids or alcohol that requires medical
detoxification/management
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